Abstract
In contrast to primary lung neoplasms, primary pleural neoplasms are uncommon. Pleural neoplasms may be difficult to diagnose and must be distinguished from metastatic carcinomas and sarcomas involving the pleura, and from benign reactive processes causing pleural thickening. A correct diagnosis is important so that appropriate therapy, although it may be only palliative, can be instituted.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Hillerdal G. Malignant mesothelioma: review of 4710 published cases. Br J Dis Chest 1983;77:321–343.
Hillerdal G. Mesothelioma: cases associated with nonoccupational and low dose exposures. Occup Environ Med 1999;56:505–513.
Aisner J, Wiernick PH. Malignant mesothelioma. Current status and future prospects. Chest 1978;74:438–443.
Chahinian AP. Malignant mesothelioma. In: Holland JF, Frei E III, eds. Cancer medicine. Philadelphia: Lea & Febiger, 1982:1744–1751.
Wagner E. Das tuberkelahnliche lymphadenom. Arch Heilk 1870;11:495–525.
Robertson HE. “Endothelioma” of the pleura. Am J Cancer 1924;8:317–375.
Doll R. Mortality from lung cancer in asbestos workers. Br J Ind Med 1955;12:81–86.
Klemperer P, Rabin CB. Primary neoplasms of pleura: report of 5 cases. Arch Pathol 1931;11:385–412.
Stout AP, Murray MR. Localized pleural mesothelioma: investigation of its characteristics and histogenesis by the method of tissue culture. Arch Pathol 1942;34:951–964.
Foster EA, Ackerman LV. Localized mesotheliomas of the pleura: the pathologic evaluation of 18 cases. Am J Clin Pathol 1960;34:349–364.
Wedler HW. Uber den Lungenkrebs bei Asbestose. Dtsch Arch Klin Med 1943;191:189–209.
Wedler HW. Uber den Lungenkrebs bei Asbestose. Dtsch Mcd Wochenschr 1943;69:575–576.
Merewether ERA. Annual report of the chief inspector of factories for the year 1947. London: His Majesty’s Stationery Office, 1949:78–81.
Mallory TB, Castleman B, Parris EE. Case records of the Massachusetts General Hospital #33111. N Engl J Med 1947;236:407–412.
Willis RA. Pathology of tumours, 4th ed. London: Butterworths, 1967.
Weiss A. Pleurakrebs bei Lungenasbestose, in vivo morphologisch Geishert. Medizienische 1953;3:93–94.
Leicher F. Primarer deckzellen Tumor des Bauchtells bei Asbestose. Arch Gewerbepathol Gewerbehyg 1954;13:382–392.
Keal EE. Asbestosis and abdominal neoplasms. Lancet 1960;2:1211–1216.
Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in North Western Cape Province. Br J Ind Med 1960;17:260–271.
Wagner JC. The discovery of the association between blue asbestos and mesotheliomas and the aftermath. Br J Ind Med 1991;48:399–403.
Wagner JC. Asbestos and mesothelioma: a personal reminiscence. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992:xvii–xxv.
Roggli VL, Pratt PC, Brody AR. Asbestos fiber type in malignant mesothelioma: an analytical scanning microscopic study of 94 cases. Am J Ind Med 1993;23:605–614.
Dodson RF, O’Sullivan M, Corn CJ, et al. Analysis of asbestos fiber burden in lung tissue from mesothelioma patients. Ultrastruct Pathol 1997;21:321–336.
Smither WJ, Gilson JC, Wagner JC. Mesotheliomas and asbestos dust. Br Med J 1962;2:1194–1195.
McCaughey WTE, Wade OL, Elmes PC. Exposure to asbestos dust and diffuse pleural mesothelioma. Br Med J 1962;2:1397.
Wagner JC, Munday DE, Harington JS. Histochemical demonstration of hyaluronic acid in pleural mesotheliomas. J Pathol Bacteriol 1962;84:73–78.
Wagner JC. Experimental production of mesothelial tumours of the pleura by implantation of dusts in laboratory animals. Nature 1962;196:180–181.
Selikoff IJ, Churg J, Hammond EC. Relation between exposure to asbestos and mesothelioma. N Engl J Med 1965;272:560–565.
Selikoff IJ, Churg J, Hammond EC. Asbestos exposure and neoplasia. JAMA 1964;188:22–26.
Newhouse ML, Thompson H. Epidemiology of mesothelial tumors in the London area. Ann NY Acad Sci 1965;132:579–588.
Newhouse ML, Thompson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med 1965;22:261–269.
Goodwin MC. Diffuse mesotheliomas with comment on their relationship to localized fibrous mesotheliomas. Cancer 1967;10:298–319.
South Australian Cancer Registry. Epidemiology of cancer in South Australia: incidence, mortality and survival 1977 to 1999. Adelaide: Department of Human Services, 2000.
New South Wales Cancer Council (NSWCC). Cancer in New South Wales: incidence and mortality 1997. Sydney: NSWCC, 1999.
Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: cancer incidence, mortality and prevalence worldwide. Lyon: International Agency for Research on Cancer, 2001.
Leigh J, Hendrie L, Berry D. Malignant mesothelioma in Australia, 1945–2000. J Occup Health Safety Aust NZ 2001;17:453–470.
Galateau-Sallé F, ed. International Mesothelioma Panel: Brambilla E, Cagle PT, Churg AM, et al. Pathology of malignant mesothelioma. London: Springer, 2006.
Henderson DW, Rödelsperger K, Woitowitz H-J, Leigh J. After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997–2004. Pathology 2004;36:517–550.
Motley RL. The lid comes off. Trial 1980;15:21–24.
Brodeur P. Expendable Americans. New York: Viking, 1974.
Brodeur P. The asbestos industry on trial. I. A failure to warn. II. Discovery. III. Judgement. IV. Bankruptcy. New Yorker 1985;61:49–52+ (June 10); 45–48+ (June 17); 37–41+ (June 24);36–38+ (July 1).
World Trade Organization (WTO) Dispute Settlement Report WT/DS135. European Communities—Measures Concerning Asbestos and Asbestos-Containing Products. Geneva: WTO, 2000. See also WTO Dispute Settlement Reports 2001;8:3303–4047 (DSR 2001: VIII). Cambridge: Cambridge University Press, 2004.
Leigh J, Robinson BWS. The history of mesothelioma in Australia 1945–2001. In: Robinson BWS, Chahinian AP, eds. Mesothelioma. London: Martin Dunitz, 2002:55–86.
Health and Safety Executive (HSE). Mesothelioma occupation statistics: male and female deaths aged 16–74 in Great Britain 1980–2000 (excluding 1981). London: HSE, 2003.
Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211–218.
Teschke K, Morgan MS, Checkoway H, et al. Mesothelioma surveillance to locate sources of exposure to asbestos. Can J Public Health/Rev Can Santé Publique 1997;88:163–168.
Tossavainen A. Asbestos, asbestosis and cancer: exposure criteria for clinical diagnosis. Asbestos, Asbestosis and Cancer. People and Work Research Reports 14. Helsinki: Finnish Institute of Occupational Health (FIOH), 1997;14:8–27.
Tossavainen A, Takahashi K. Epidemiological trends for asbestos-related cancers. People and Work Research Reports 36. Helsinki: FIOH, 2000;36:26–30.
HSE. Mesothelioma. 2006: http://www.hse.gov.uk/statistics/causdis/meso.htm.
McDonald AD, Harper A, El Attar DA, McDonald JC. Epidemiology of primary malignant mesothelial tumors in Canada. Cancer 1970;26:914–919.
Theriault GP, Grand-Bois L. Mesothelioma and asbestos in the province of Quebec, 1969–1972. Arch Environ Health 1978;33:15–19.
Biava PM, Ferri R, Spacal B, et al. Cancro de lovora a Trieste: II mesothelioma della pleura. Sapere 1976;79:41–45.
Greenberg M, Lloyd-Davies TA. Mesothelioma register 1967–1968. Br J Ind Med 1974;31:91–104.
McDonald All, McDonald JC. Malignant mesothelioma in North America. Cancer 1980;46:1650–1656.
Cutler SJ, Young JL. Third National Cancer Survey: incidence data. Natl Cancer Inst Monogr 1975;41:442.
Bruckman L, Rubino RA, Christine B. Asbestos and mesothelioma incidence in Connecticut. J Air Pollut Control Assoc 1977;27:121–126.
Churg A. Malignant mesothelioma in British Columbia in 1982. Cancer 1985;55:672–674.
Ferguson D. Malignant mesothelioma—the rising epidemic. Med J Austral 1989;150:233–235.
McDonald JC, McDonald AD. Epidemiology of mesothelioma from estimated incidence. Prev Med 1977;6:426–446.
Hughes JM, Weill H. Asbestos exposure—quantitative assessment of risk. Am Rev Respir Dis 1986;133:5–13.
Selikoff IJ, Hammond EC, Seidman H. Mortality experience of insulation workers in the United States and Canada 1943–1976. Ann NY Acad Sci 1979;330:91–116.
Huncharek M. Changing risk groups for malignant mesothelioma. Cancer 1992;69:2704–2711.
Environmental Working Group (EWG) Action Fund Report. The Asbestos Epidemic in America. 2004. http://wwwewgorg/reports/asbestos/facts/fact1php.
Price B. Analysis of current trends in the United States mesothelioma incidence. Am J Epidemiol 1997;145:211–218.
Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987;78:1053–1060.
Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535–539.
Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britian from 2002 to 2050. Br J Cancer 2005;92:587–593.
Health and Safety Executive Data. Cited in Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005;49(suppl):S3–S8.
Treasure T, Waller D, Swift S, Peto J. Radical surgery for mesothelioma. BMJ 2004;328:237–238.
Roggli VL. Changing patterns of mesothelioma referral. Asbestos Med 2004;387–397.
Lemen RA. Epidemiology of asbestos-related diseases and the knowledge that led to what is known today. In: Dodson RF, Hammar SP, eds. Asbestos: risk assessment, epidemiology and health effects. Boca Raton: CRC Taylor Francis, 2006:217.
Wagner JC. Mesothelioma and mineral fibers. Cancer 1986;57:1905–1911.
Rom WM, Lockey JE. Diffuse malignant mesothelioma: a review. West J Med 1982;137:548–554.
Legha SS, Muggia FM. Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med 1977;87:613–621.
Borow M, Conston A, Livornese L, Schalet N. Mesothelioma following exposure to asbestos: a review of 72 cases. Chest 1973;64:641–646.
Cochrane JC, Webster I. Mesothelioma in relation to asbestos fibre exposure. A review of 70 serial cases. S Afr Med J 1978;54:279–281.
Tagnon I, Blot WJ, Stroube RB, et al. Mesothelioma associated with the shipbuilding industry in coastal Virginia. Cancer Res 1980;40:3875–3879.
Whitwell F, Rawcliffe RM. Diffuse malignant pleural mesothelioma and asbestos exposure. Thorax 1971;26:6–22.
Hammar SP. Mesothelioma. In: Sheppard MN, ed. Practical pulmonary pathology. Boston: Little, Brown and Edward Arnold, 1995:264–288.
Taylor RA, Johnson LP. Mesothelioma: current perspectives. West J Med 1981;134:379–383.
Vogelzang NJ, Schultz SM, Iannucci AM, Kennedy BJ. Malignant mesothelioma: the University of Minnesota experience. Cancer 1984;53:377–383.
Peto J, Henderson BE, Pike MC. Trends in mesothelioma in the United States and the forecast epidemic due to asbestos exposure during World War II. In: Peto R, Schneiderman M, eds. Quantification of occupational cancer. Banbary Report 9. New York: Cold Spring Harbor Laboratory 1981:51–69.
Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases. Cancer 1982;50:2423–2432.
Oels HC, Harrison EG, Carr DT, Bernatz PE. Diffuse malignant mesothelioma of the pleura: a review of 37 cases. Chest 1971;60:564–470.
Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: review of 123 patients. Cancer 1982;49:2431–2435.
Ratzer ER, Pool JL, Melamed MR. Pleural mesotheliomas: clinical experiences with thirty-seven patients. Am J Radiol 1967;99:863–880.
Newhouse ML, Berry G. Patterns of mortality in asbestos factory workers in London. Ann NY Acad Sci 1979;330:53–60.
Newhouse ML, Berry G. Predictions of mortality from mesothelial tumours in asbestos factory workers. Br J Ind Med 1976;33:147–151.
Epler GR, Gerlad MXF, Gaensler EA, Carrington CB. Asbestos-related disease from household exposure. Respiration 1980;39:229–240.
Chen W, Mottet NK. Malignant mesothelioma with minimal asbestos exposure. Hum Pathol 1978;9:253–258.
Iwatsubo Y, Pairon JC, Menard BO, et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-controlled study. Am J Epidemiol 1998;148:133–142.
World Health Organization. Environmental Health Criteria 203. Chrysotile asbestos. Geneva: WHO, 1998.
Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000;44:565–601.
Rödelsperger K, Jockel H, Pohlabein H, Romer W, Woitowitz H. Asbestos and man-made vitreous fibers as risk factors for diffuse malignant mesothelioma: results from a German hospital-based case-control study. Am J Ind Med 2001;39:262–275.
Rolland P, Ducamp S, Gramond C, et al. Risk of pleural mesothelioma: a French population-based case-control study. Lung Cancer 2006;54(suppl):S9–S10.
Evaluation of EPA’s analytical data from the El Dorado Hills Asbestos Evaluation Project. April 20, 2006:14.
Elimination of asbestos-related diseases. Policy paper. World Health Organization, 2006.
Anderson HA, Lils R, Daum SM, et al. Asbestosis among household contacts of asbestos factory workers. Ann NY Acad Sci 1979;330:387–399.
Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet 1978;1:1061–1063.
Kane MJ, Chahinian P, Holland JF. Malignant mesothelioma in young adults. Cancer 1990;65:1449–1455.
Cazzadori A, Malesani F, Romeo L. Malignant pleural mesothelioma caused by non-occupational childhood exposure to asbestos. Br J Ind Med 1992;49:599.
Dodoli D, Del Nevo M, Fiumalbi C, et al. Environmental household exposure to asbestos and occurrence of pleural mesothelioma. Am J Ind Med 1992;21:681–687.
Hammar SP, Roggli VL, Oury T. Malignant mesothelioma in women. Lung Cancer 1997;18(Suppl 1):236.
Baris YI. Pleural mesotheliomas and asbestos pleurisies due to environmental asbestos exposure in Turkey: an analysis of 120 cases. Hacettepe Bull Med/Surg 1975;8:165–185.
Baris YI, Sahin AA, Ozesmi M, et al. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax 1978;33:181–192.
Artvinli M, Baris YI. Malignant mesotheliomas in a small village in the Anatolian region of Turkey: an epidemiologic study. J Natl Cancer Inst 1979;63:17–22.
Baris YI, Saracci R, Simonato L, Skidmore JW, Artvinli M. Malignant mesothelioma and radiological chest abnormalities in two villages in central Turkey. Lancet 1981;1:984–987.
Artvinli M, Baris YL. Environmental fiber-induced pleuro-pulmonary diseases in an Anatolian village: an epidemiologic study. Arch Environ Health 1982;37:177–181.
Lillis R. Fibrous zeolites and endemic mesothelioma in Cappadocia, Turkey. J Occup Med 1981;23:548–550.
Sebastien P, Gaudichet A, Bignon J, Baris YL. Zeolite bodies in human lungs from Turkey. Lab Invest 1981;44:420–425.
Wagner JC, Skidmore JW, Hill RJ, Griffiths DM. Erionite exposure and mesotheliomas in rats. Br J Cancer 1985;51:727–750.
Rohl AN, Langer AM, Moncure G, Selikoff IJ, Fischbein A. Endemic pleural disease associated with exposure to mixed fibrous dust in Turkey. Science 1982;216:518–520.
Pistolesi M, Rusthoven J. Malignant pleural mesothelioma. Update, current management, and newer therapeutic strategies. Chest 2004;126:1318–1329.
Roushady-Hammady I, Siegel J, Emri S, et al. Genetic susceptibility factor of malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001;357:444–445.
Hillerdal G, Berg J. Malignant mesothelioma secondary to chronic inflammation and old scars: two new cases and review of the literature. Cancer 1985;55:1968–1972.
Gentiloni N, Febbraro S, Barone C, et al. Peritoneal mesothelioma in recurrent familial peritonitis. J Clin Gastroenterol 1997;24:276–279.
Schneider J, Woitowitz H-J. Asbestos-related nonoccupational malignant mesothelioma. In: Peters GA, Peters BJ, eds. Sourcebook on asbestos diseases. Charlottesville: Lexis, 1998;17:43–69.
Sakellariou K, Malamou-Mitsi V, Haritou A, et al. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? Eur Respir J 1996;9:1206–1210.
Henderson DW, Comin CE, Hammar SP, et al. Malignant mesothelioma of the pleura: current surgical pathology. In: Corrin B, ed. Pathology of lung tumors. New York: Churchill Livingstone, 1997:241–280.
Kerrigan SA, Cagle P, Churg A. Malignant mesothelioma of the peritoneum presenting as an inflammatory lesion: a report of four cases. Am J Surg Pathol 2003;27:248–253.
Andersson M, Wallin H, Jonsson M, et al. Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status. Int J Cancer 1995;63:330–336.
de la Pena A, Lucas I. Malignant peritoneal mesothelioma as late complication of radiotherapy for Hodgkin’s disease [letter; Spanish]. An Med Intern 1997;14:319.
Gold B, Kathren RL. Causes of death in a cohort of 260 plutonium workers. Health Phys 1998;75:236–240.
Van Kaick G, Dalheimer A, Hornik S, et al. The German thorotrast study: recent results and assessment of risks. Radiat Res 1999;152:S64–71.
Amin AM, Mason C, Rowe P. Diffuse malignant mesothelioma of the peritoneum following abdominal radiotherapy. Eur J Surg Oncol 2001;27:214–215.
Henley JD, Loehrer PJ Sr, Ulbright TM. Deciduoid mesothelioma of the pleura after radiation therapy for Hodgkin’s disease presenting as a mediastinal mass. Am J Surg Pathol 2001;25:547–548.
Melato M, Rizzardi C. Malignant pleural mesothelioma following chemotherapy for breast cancer. Anticancer Res 2001;21:3093–3096.
Velissaris TJ, Tang AT, Millward-Sadler GH, et al. Pericardial mesothelioma following mantle field radiotherapy. J Cardiovasc Surg (Torino) 2001;42:425–427.
Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on longterm survivors. J Natl Cancer Inst 2005;97:1354–1365.
Neugut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer 1997;80:948–950.
Austin MB, Fechner RE, Roggli VL. Pleural malignant mesothelioma following Wilms’ tumor. Am J Clin Pathol 1986;86:227–230.
Anderson KA, Hurley WC, Hurley BT, Ohrt DW. Malignant pleural mesothelioma following radiotherapy in a 16-year-old boy. Cancer 1985;56:273–276.
Mizuki M, Yukishige K, Abe Y, Tsuda T. A case of malignant pleural mesothelioma following exposure to atomic radiation in Nagasaki. Respirology 1997;2:201–205.
da Silva Horta J, et al. Malignancy and late effects following administration of Thorotrast. Lancet 1965;2:201–205.
Maurer R, Egloff B. Malignant peritoneal mesothelioma after colangiography with Thorotrast. Cancer 1975;36:1381–1385.
Babcock TL, et al. Radiation-induced peritoneal mesothelioma. J Surg Oncol 1976;8:369–372.
Stock RJ, Fu YS, Carter JR. Malignant peritoneal mesothelioma following radiotherapy for seminoma of the testis. Cancer 1979;44:914–919.
Brenner J, et al. Malignant mesothelioma of the pleura: review of 123 patients. Cancer 1982;49:2431–2435.
Antman KH, Corson JM, Li FP, et al. Malignant mesothelioma following radiation exposure. J Clin Oncol 1983;1:695–700.
Antman KH, Ruxer RL, Aisner J, Vawter G. Mesothelioma following Wilms’ tumor in childhood. Cancer 1984;54:367–369.
Gilks B, et al. Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 1988;61:2019–2021.
Horie A, Hiraoka K, Yamamoto O, et al. An autopsy case of peritoneal malignant mesothelioma in a radiation technologist. Acta Pathol Jpn 1990;40:57–62.
Lerman Y, et al. Radiation-associated malignant pleural mesothelioma. Thorax 1991;46:463–464.
Hofmann J, et al. Malignant mesothelioma following radiation therapy. Am J Med 1994;97:379–382.
Shannon VR, Nesbitt JC, Libshitz HI. Malignant pleural mesothelioma after radiation therapy for breast cancer: a report of two additional patients. Cancer 1995;76:437–441.
Cavazza A, Travis LB, Travis WD, et al. Post irradiation malignant mesothelioma. Cancer 1996;77:1379–1385.
Weissmann LB, et al. Malignant mesothelioma following treatment for Hodgkin’s disease. J Clin Oncol 1996;14:2098–2100.
Pappo AS, Santana VM, Furman WL, et al. Post irradiation malignant mesothelioma. Cancer 1997;79:192–193.
Tassile D, Roth AD, Kurt AM, et al. Colon cancer and peritoneal mesothelioma occurring 29 years after abdominal radiation for testicular seminoma: a case report and review of the literature. Oncol 1998;55:289–292.
Kramer G, et al. Long-term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease treated with 90yttriumsilicate. Lung Cancer 2000;27:205–208.
Teta MJ, et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007;109:1432–1438.
Talerman A, Montero JR, Chilcote RR, Okagaki T. Diffuse malignant peritoneal mesothelioma in a 13-yearold girl: report of a case and review of the literature. Am J Surg Pathol 1985;9:73–80.
Fraire AE, Cooper S, Greenberg SD, Buffler PA, Langston C. Mesothelioma of childhood. Lab Invest 1987;56:25A.
Fraire AE, Cooper S, Greenberg SD, Buffler P, Langston C. Mesothelioma of childhood. Cancer 1988;62:838–847.
Lin-Chu M, Lee Y, Ho MY. Malignant mesothelioma in infancy. Arch Pathol Lab Med 1989;113:409–411.
Priest JR, McDermott MB, Bhatia S, et al. Pleuropulmonary blastoma: a clinicopathologic study of 50 cases. Cancer 1997;80:147–161.
McDonald JC, McDonald A. Mesothelioma and asbestos exposure. In: Pass HI, Vogelzang NJ, Carbone M, eds. Malignant mesothelioma: advances in pathogenesis, diagnosis, and translational therapies. New York: Springer, 2005:267–292.
McDonald JC, McDonald AD. Mesothelioma: is there a background? In: Jaurand M-C, Bignon J, eds. The mesothelial cell and mesothelioma. New York: Marcel Dekker, 1994:37–45.
HSE. Health and Safety Statistics 1998/99. London: HSE Books, 1999.
Strickler HD, Goedert JJ, Devesa SS, et al. Trends in US pleural mesothelioma incidence rates following simian virus 40 contamination of early Poliovirus vaccines. J Natl Cancer Inst 2003;95:38–45.
Roggli VL, Oury TD, Moffatt EJ. Malignant mesothelioma in women. Anat Pathol 1997;2:147–163.
Roggli VL, Sharma A, Butnor KJ, et al. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002;26:55–65.
Hillerdal G. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med 1999;56:505–513.
Di Maria GU, Comba P. Malignant pleural mesothelioma: the puzzling role of gene-environment interaction. Chest 2004;125:1604–1607.
Lynch HT, Katz D, Markvicka SE. Familial mesothelioma: review and family study. Cancer Genet Cytogenet 1985;15:25–35.
Martensson G, Larsson S, Zettergren L. Malignant mesothelioma in two pairs of siblings: Is there a hereditary predisposing factor? Eur J Respir Dis 1984;65:179–184.
Hammar S. Familial mesothelioma: a report of two families. Hum Pathol 1989;20:107–112.
Huncharek M, Kelsey K, Muscat J, Christiani D. Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study. Cancer Lett 1996;102:205–208.
Heineman EF, Bernstein L, Stark AD, Spirtas R. Mesothelioma, asbestos, and reported history of cancer in first-degree relatives. Cancer 1996;77:549–554.
Ascoli V, Scalzo CC, Bruno C, Facciolo F, et al. Familial pleural malignant mesothelioma: clustering in three sisters and one cousin. Cancer Lett 1998;130:203–207.
Bianchi C, Brollo A, Ramani L, Bianchi T, Giarelli L. Familial mesothelioma of the pleura-a report of 40 cases. Ind Health 2004;42:235–239.
Ohar JA, Ampleford EJ, Howard SE, Sterling DA. Identification of a mesothelioma phenotype. Respir Med 2007;101:503–509.
Ascoli V, Aalto Y, Carnovale-Scalzo C, Nardi F, et al. DNA copy number changes in familial malignant mesothelioma. Cancer Genet Cytogenet 2001;127:80–82.
Musti M, Cavone D, Aalto Y, Scattone A, et al. A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly. Cancer Genet Cytogenet 2002;138:73–76173.
Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci 1995;92:10854–10858.
Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer 2003;103:105–109.
Dawson A, Gibbs A, Browne K, et al. Familial mesothelioma: details of 17 cases with histopathologic findings and mineral analysis. Cancer 1992;70:1183–1187.
Serio G, Scattone A, Gentile M, et al. Familial pleural mesothelioma with environmental asbestos exposure: losses of DNA sequences by comparative genomic hybridization (CGH). Histopathology 2004;45:643–645.
Nelson HH, Christiani DC, Wiencke JK, et al. K-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis. Cancer Res 1999;59:4570–4573.
Lynch HT, Anton-Culver H, Kurosaki T. Is there a genetic predisposition to malignant mesothelioma? In: Jaurand M-C, Bignon J, eds. The mesothelial cell and mesothelioma. New York: Marcel Dekker, 1994:47–69.
Pylkkänen L, Wolff H, Stjernvall T, et al. Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients. Int J Oncol 2002;20:285–290.
Pylkkänen L, Wolff H, Stjernvall T, et al. Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch 2004;444:43–48.
Hirvonen A, Saarikoski ST, Linnainmaa K, et al. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst 1996;88:1853–1856.
Puntoni R, Filiberti R, Cerrano PG, et al. Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma. Mutat Res 2003;544:385–396.
Pott F. Asbestos use and carcinogenicity in Germany and a comparison with animal studies. Ann Occup Hyg 1994;38:589–600.
Klein G, Powers A, Croce C. Association of SV40 with human tumors. Oncogene 2002;21:1141–1149.
Immunization Safety Review Committee. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: National Academies Press, 2003.
Hubner R, Van ME. Reappraisal of the strong association between simian virus 40 and human malignant mesothelioma of the pleura (Belgium). Cancer Causes Control 2002;13:121–129.
British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001;56:250–265.
Lee YCG, de Klerk NH, Henderson DW, Musk AW. Malignant mesothelioma. In: Hendrick DJ, Burge PS, Beckett WS, Churg A, eds. Occupational disorders of the lung: recognition, management, and prevention. London: Saunders, 2002:359–379.
Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004;364:1157–1166.
Manfredi JJ, Dong J, Liu WJ, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res 2005;65:2602–2609.
Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945–2002. Int J Occup Environ Health 2003;9:206–217.
Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994;51:804–811.
Furuya S, Natori Y, Ikeda R. Asbestos in Japan. Int J Occup Environ Health 2003;9:260–265.
Albin M, Magnani C, Krstev S, et al. Asbestos and cancer: an overview of current trends in Europe. Environ Health Perspect 1999;107:289–298.
Miller A. Mesothelioma in household members of asbestos-exposed workers: 32 United States cases since 1990. Am J Ind Med 2005;47:458–462.
Schneider J, Straif K, Woitowitz HJ. Pleural mesothelioma and household asbestos exposure. Rev Environ Health 1996;11:65–70.
Browne K. Asbestos-related mesothelioma: epidemiological evidence for asbestos as a promoter. Arch Environ Health 1983;38:261–266.
Dupres JS, Mustard JF, Uffen RJ. Report of the Royal Commission on Matters of Health and Safety Arising from the Use of Asbestos in Ontario (2 vols). Toronto: Ontario Ministry of Government Services: Queen’s Printer for Ontario, 1984.
Huncharek M, Capotorto JV, Muscat J. Domestic asbestos exposure, lung fibre burden, and pleural mesothelioma in a housewife. Br J Ind Med 1989;46:354–355.
Gibbs AR, Griffiths DM, Pooley FD, Jones JSP. Comparison of fibre types and size distributions in lung tissues of paraoccupational and occupational cases of malignant mesothelioma. Br J Ind Med 1990;47:621–626.
Anderson HA, Lilis R, Daum SM, Selikoff IJ. Asbestosis among household contacts of asbestos factory workers. Ann NY Acad Sci 1979;330:387–399.
Tweedale G. Magic mineral to killer dust: Turner & Newall and the asbestos hazard. Oxford: Oxford University Press, 2000.
Layman L. The blue asbestos industry at Wittenoom in Western Australia: a short history. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992:305–327.
Musk AW, de Klerk NH, Eccles JL, et al. Wittenoom, Western Australia: a modern industrial disaster. Am J Ind Med 1992;21:735–747.
Berry G, de Klerk NH, Reid A, et al. Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia. Occup Environ Med 2004;61:e14.
Jones JSP, Smith PG, Pooley FD, et al. The consequences of exposure to asbestos dust in a wartime gas-mask factory. In: Wagner JC, ed. Biological effects of mineral fibres, vol. 2 IARC Scientific Publications no. 30. Lyon: IARC, 1980:637–653.
Brown SK. A review of occupational and environmental exposure to asbestos dust. Melbourne, Australia: CSIRO Division of Building Research, 1981.
Jarvholm B, Sanden A. Lung cancer and mesothelioma in the pleura and peritoneum among Swedish insulation workers. Occup Environ Med 1998;55:766–770.
Henderson DW, Shilkin KB, Whitaker D, et al. The pathology of mesothelioma, including immunohistology and ultrastructure. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992:69–139.
Hemminki K, Li X. Time trends and occupational risk factors for pleural mesothelioma in Sweden. J Occup Environ Med 2003;45:456–461.
Comin CE, de Klerk NH, Henderson DW. Malignant mesothelioma: current conundrums over risk estimates, and whither electron microscopy for diagnosis? Ultrastruct Pathol 1997;21:315–320.
Neumann V, Muller KM, Fischer M. Peritoneal mesothelioma—incidence and etiology [German]. Pathologe 1999;20:169–176.
Neumann V, Gunthe S, Muller KM, Fischer M. Malignant mesothelioma—German mesothelioma register 1987–1999. Int Arch Occup Environ Health 2001;74:383–395.
Rogers AJ, Leigh J, Berry G, et al. Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma: a case-control study. Cancer 1991;67:1912–1920.
Hemminki K, Li X. Time trends and occupational risk factors for peritoneal mesothelioma in Sweden. J Occup Environ Med 2003;45:451–455.
Ferguson DA, Berry G, Jelihovsky T, et al. The Australian mesothelioma surveillance program 1979–1985. Med J Aust 1987;147:166–172.
Bianchi C, Brollo A, Ramani L, et al. Asbestos exposure in malignant mesothelioma of the pleura: a survey of 557 cases. Ind Health 2001;39:161–167.
Multiple authors. Consensus report: asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997;23:311–316.
Craighead JE, Abraham JL, Churg A, et al. The pathology of asbestos-associated diseases of the lungs and pleural cavities: diagnostic criteria and proposed grading schema. Arch Pathol Lab Med 1982;106:544–596.
Henderson DW, Jones ML, DeKlerk N, et al. The diagnosis and attribution of asbestos-related diseases in an Australian cohort: report of the Adelaide Workshop on Asbestos-Related Diseases. October 6–7. Int J Occup Environ Health 2004;10:40–46.
Wagner JC, Pooley FD. Mineral fibres and mesothelioma. Thorax 1986;41:161–166.
Pott F. Problems in defining carcinogenic fibres. Ann Occup Hyg 1987;31:799–802.
Pott F, Huth F, Friedrichs KH. Tumorigenic effects of fibrous dusts in experimental animals. Environ Health Perspect 1974;9:313–315.
Pott F, Ziem U, Reiffer FJ, Huth F, Ernst H, Mohr U. Carcinogenicity studies on fibres, metal compounds and some other dusts in rats. Exp Pathol 1987;32:129–152.
Pott F, Roller M, Ziem U, et al. Carcinogenicity studies on natural and man-made fibres with the intraperitoneal test in rats. Symposium on Mineral Fibres in the Non-Occupational Environment, Lyon, September 8–9, 1987:1–4.
Stanton MF, Wrench C. Mechanisms of mesothelioma including with asbestos and fibrous glass. J Natl Cancer Inst 1972;48:797–821.
Stanton MF, Layard M, Tegeris E, et al. Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J Natl Cancer Inst 1981;67:965–975.
Harington JS. Fiber carcinogenesis: epidemiologic observations and the Stanton hypothesis. J Natl Cancer Inst 1981;67:977–989.
Davis JMG, Jones AD. Comparisons of the pathogenicity of long and short fibres of chrysotile asbestos in rats. Br J Exp Pathol 1988;69:717–737.
Davis JMG, Addison J, Bolton RE, et al. The pathogenicity of long versus short fibre samples of amosite asbestos administered to rats by inhalation and intraperitoneal injection. Br J Exp Pathol 1986;67:415–430.
Donaldson K, Golyasnya G, Davis JMG. Long and short amosite asbestos samples: comparison of chromosome-damaging effects to cells in culture with in vivo pathogenicity. In: Davis JMG, Jaurand M-C, eds. Cellular and molecular effects of mineral and synthetic dusts and fibres. NATO ASI series, vol. H85. Berlin: Springer-Verlag, 1994.
Yegles M, Janson X, Dong HY, et al. Role of fibre characteristics on cytotoxicity and induction of anaphase/telophase aberrations in rat pleural mesothelial cells in vitro: correlations with in vivo animal findings. Carcinogenesis 1995;16:2751–2758.
Suzuki Y, Yuen SR. Asbestos tissue burden study on human malignant mesothelioma. Ind Health 2001;39:150–160.
Dodson RF, Williams MG, Corn CJ, Brollo A, Bianchi C. Asbestos content of lung tissue, lymph nodes, and pleural plaques from former shipyard workers. Am Rev Respir Dis 1990;142:843–847.
Sebastien P, Janson X, Gaudicher A, Hirsh A, Bignon J. Asbestos retention in human respiratory tissues: Comparative measurements in lung parenchyma and in parietal pleura. In: Wagner JC, ed. Biological effects of mineral fibers. Lyon: IARC, 1980:237–246.
Suzuki Y, Yuen SR. Asbestos fibers contributing to the induction of human malignant mesothelioma. Ann NY Acad Sci 2002;982:160–176.
Dodson RF, O’Sullivan M, Huang J, Holiday DB, Hammar SP. Asbestos in extrapulmonary sites, omentum and mesentery. Chest 2000;117:486–493.
Boutin C, Dumortier P, Rey F, Viallat JR, DeVuyst P. Black spots concentrate oncogenic asbestos fibers in the parietal pleura: thoracoscopic and mineralogic study. Am J Respir Crit Care Med 1996;153:444–449.
Mitchev K, Dumortier P, DeVuyst P. “Black spots” and hyaline pleural plaques on parietal pleura of 150 urban necropsy cases. Am J Surg Pathol 2002;26:1196–1206
Zeren EH, Gumurdulu D, Roggli VL, Tuncer I, Zorludemir S, Erikisi M. Environmental malignant mesothelioma in Southern Anatolia: a study of fifty cases. Environ Health Perspect 2000;108:1047–1050.
Selcuk ZT, Coplu L, Emri S, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Chest 1992;102:790–796.
Baris I, Simonato L, Artvinli M, et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer 1987;39:10–17.
Johnson NF, Edwards RE, Munday DE, Rowe N, Wagner JC. Pluripotential nature of mesotheliomata induced by inhalation of erionite in rats. Br J Exp Pathol 1984;65:377–388.
McDonald JC, Harris J, Armstrong B. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. Occup Environ Med 2004;61:363–366.
Anderson BA, Dearwent SM, Durant JT, et al. Exposure pathway evaluations for sites that processed asbestos-contaminated vermiculite. Int J Hyg Environ Health 2005;208:55–65.
Churg A. The diagnosis of asbestosis. Hum Pathol 1981;20:97–99.
Roggli VL, Pratt PC. Numbers of asbestos bodies on ironstained tissue sections in relation to asbestos body counts in lung tissue digests. Hum Pathol 1983;14:355.
Dodson RF, O’Sullivan MF, Brooks DR, Bruce JR. Asbestos content of omentum and mesentery in nonoccupationally exposed individuals. Toxicol Ind Health 2001;17:138–143.
Dodson RF, Greenberg SD, Williams MG, et al. Asbestos content in lungs of occupationally and nonoccupationally exposed individuals. JAMA 1984;252:68–71.
Breeding PH, Buss DH. Ferruginous (asbestos) bodies in the lungs of rural dwellers, urban dwellers, and patients with pulmonary neoplasms. South Med J 1976;69:401–404.
Roggli VL, Pratt PC, Brody AR. Asbestos content of lung tissue in asbestos associated diseases: a study of 110 cases. Br J Ind Med 1986;43:18–28.
Langer AM, Selikoff IJ, Sastre A. Chrysotile asbestos in the lungs from persons in New York City. Arch Environ Health 1971;22:348–361.
Dodson RF, Atkinson AL. Measurements of asbestos burden in tissues. Ann NY Acad Sci 2006;1076:281–291.
Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases. Cancer 1982;50:2423–2432.
Roggli VL. Human disease consequences of fiber exposures: a review of human pathology and fiber burden data. Environ Health Perspect 1990;88:295–303.
Srebro SH, Roggli VL. Asbestos-related disease associated with exposure to asbestiform tremolite. Am J Ind Med 1994;26:809–819.
Srebro SH, Roggli VL, Samsa GP. Malignant mesothelioma associated with low pulmonary tissue asbestos burdens: a light and scanning electron microscopic analysis of 18 cases. Mod Pathol 1995;8:614–621.
Roggli VL. The role of analytical SEM in the determination of causation in malignant mesothelioma. Ultrastruct Pathol 2006;30:31–35.
Dodson RF, Graef R, Shepherd S, O’Sullivan M, Levin J. Asbestos burden in cases of mesothelioma from individuals from various regions of the United States. Ultrastruct Pathol 2005;29:415–433.
Paoletti L, Batisti D, Bruno C, et al. Unusually high incidence of malignant pleural mesothelioma in a town of eastern Sicily: an epidemiological and environmental study. Arch Environ Health 2000;55:392–398.
Langer AM, Nolan RP, Constantopoulos SH, Moutsopoulos HM. Association of Metsovo lung and pleural mesothelioma with exposure to tremolite-containing whitewash. Lancet 1987;1:965–967.
Howel D, Gibbs A, Arblaster L, et al. Mineral fibre analysis and routes for exposure to asbestos in the development of mesothelioma in an English region. Occup Environ Med 1999;56:51–58.
Karjalainen A, Meurman LO, Pukkala E. Four cases of mesothelioma among Finnish anthophyllite miners. Occup Environ Med 1994;51:212–215.
Tuomi T, Segerberg-Konttinen M, Tammllehto L, et al. Mineral fiber concentration in lung tissue of mesothelioma patients in Finland. Am J Ind Med 1989;16:247–254.
Andrion A, Bosia S, Paoletti L, et al. Malignant peritoneal mesothelioma in a 17-year-old boy with evidence of previous exposure to chrysotile and tremolite asbestos. Hum Pathol 1994;25:617–622.
Glickman LT, Domanski LM, Maguire TG, et al. Mesothelioma in pet dogs associated with exposure of their owners to asbestos. Environ Res 1983;32:305–313.
Frank AL, Dodson RF, Williams MG. Carcinogenic implications of the lack of tremolite in UICC reference chrysotile. Am J Ind Med 1998;34:314–317.
Davis JMG, Bolton RE, Miller BG, Niven K. Mesothelioma dose response following intraperitoneal injection of mineral fibres. Int J Exp Pathol 1991;72:263–274.
Egilman D, Fehnel C, Bohme SR. Exposing the “myth” of ABC, “anything but chrysotile.” A critique of the Canadian asbestos mining industry and McGill University chrysotile studies. Am J Ind Med 2003;44:540–557.
De A. Petrology of dikes emplaced in the ultramafic rocks of South Eastern Quebec. PhD thesis, Princeton University, 1961.
Churg A. Chrysotile, tremolite, and malignant mesothelioma in man. Chest 1988;93:621–628.
Churg A, Wright JL, Vedal S. Fiber burden and patterns of asbestos-related disease in chrysotile miners and millers. Am Rev Respir Dis 1993;148:25–31.
Dufresne A, Begin R, Churg A, Masse S. Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Quebec. Am J Respir Crit Care Med 1996;153:711–718.
Begin R, Gauthier J, Desmeules M, Ostiguy G. Work-related mesothelioma in Quebec, 1967–1990. Am J Ind Med 1992;22:531–542.
Langer AM, McCaughey WTE. Mesothelioma in a brake repair worker. Lancet 1982;1:1101–1103.
Nolan RP, Langer AM, Addison J. Lung content analysis of cases occupationally exposed to chrysotile asbestos. Environ Health Perspect 1994;102:245–250.
Churg A, Vedal S. Fiber burden and patterns of asbestos-related disease in workers with heavy mixed amosite and chrysotile exposure. Am J Respir Crit Care Med 1994;150:663–669.
McDonald JC, Armstrong BG, Edwards CW, et al. Case-reference survey of young adults with mesothelioma: I. Lung fibre analysis. Br Occup Hyg Soc 2001;45:513–518.
Talcot J, Thurber W, Gaensler E, Antman K, Li FP. Mesothelioma in manufacturing of asbestos-containing cigarette filters. Lancet 1987;1:392.
Talcot JA, Thurber WA, Kantor AF, et al. Asbestos-associated diseases in a cohort of cigarette-filter workers. N Engl J Med 1989;321:1220–1223.
Dodson RF, Williams MG, Satterley JD. Asbestos burden in two cases of mesothelioma where the work history included manufacturing of cigarette filters. J Toxicol Environ Health 2002;65:1109–1102.
Dodson RF, Hammar SP. Pleural mesothelioma in a woman whose documented past exposure to asbestos was from smoking asbestos-containing filtered cigarettes: the comparative value of analytical transmission electron microscopic analysis of lung and lymph-node tissue. Inhal Toxicol 2006;18:679–684.
Levin JL, McLarty JW, Hurst GA, Smith AN, Frank AL. Tyler asbestos workers: mortality experiences in a cohort exposed to amosite. Occup Environ Med 1998;55:155–160.
Dodson RF, O’Sullivan M, Brooks DR, Hammar SP. Quantitative analysis of asbestos burden in women with mesothelioma. Am J Ind Med 2003;43:188–195.
Peto J, Decarli A, LaVecchia C, Levi, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666–672.
De Klerk NH, Armstrong BK. The epidemiology of asbestos and mesothelioma. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992:223–250.
Hammar SP. Pleural diseases. In: Dail DH, Hammar SP, eds. Pulmonary pathology, 2nd ed. New York: Springer-Verlag, 1994:1463–1579.
Fattman CL, Chu CT, Oury TD. Experimental models of asbestos-related diseases. In: Roggli VL, Oury TD, Sporn TA, eds. Pathology of asbestos-associated diseases, 2nd ed. New York: Springer-Verlag, 2004:256–308.
Middleton AP, Beckett ST, Davis JM. Further observations on the short-term retention and clearance of asbestos by rats, using UICC reference samples. Ann Occup Hyg 1979;22:141–152.
Du Toit RS. An estimate of the rate at which crocidolite asbestos fibres are cleared from the lung. Ann Occup Hyg 1991;35:433–438.
De Klerk NH, Musk AW, Williams V, et al. Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom Gorge, W. Australia. Am J Ind Med 1996;30:579–587.
Finkelstein MM, Dufresne A. Inferences on the kinetics of asbestos deposition and clearance among chrysotile miners and millers. Am J Ind Med 1999;35:401–412.
Rödelsperger K, Mándi A, Tossavainen A, et al. Inorganic fibres in the lung tissue of Hungarian and German lung cancer patients. Int Arch Occup Environ Health 2000;74:133–138.
Peto J, Seidman H, Selikoff IJ. Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer 1982;45:124–135.
Berry G. Models for mesothelioma incidence following exposure to fibers in terms of timing and duration of exposure and the biopersistence of the fibers. Inhal Toxicol 1999;11:111–130.
Bourdès V, Boffetta P, Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur J Epidemiol 2000;16:411–417.
Magnani C, Agudo A, Gonzalez CA, et al. Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Br J Cancer 2000;83:104–111.
Magnani C, Dalmasso P, Biggeri A, et al. Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy. Environ Health Perspect 2001;109:915–919.
Rödelsperger K, Woitowitz HJ, Bruckel B, et al. Dose-response relationship between amphibole fiber lung burden and mesothelioma. Cancer Detect Prevent 1999;23:183–193.
Pan X-I, Day HW, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma in California. Am J Respir Crit Care Med 2005;172:1019–1025.
Koskinen K, Pukkala E, Martikainen R, et al. Different measures of asbestos exposure in estimating risk of lung cancer and mesothelioma among construction workers. J Occup Environ Med 2002;44:1190–1196.
Industrial Injuries Advisory Council (UK). Asbestos-related diseases: report by the Industrial Injuries Advisory Council in Accordance with Section 171 of the Social Security Administration Act 1992 Reviewing the Prescription of the Asbestos-Related Diseases. London: HMSO, 2005.
Mossman BT. Mechanisms of asbestos carcinogenesis and toxicity: the amphibole hypothesis revisited. Br J Ind Med 1993;50:673–676.
Mossman BT, Gee JBL. Asbestos-related cancer and the amphibole hypothesis: 4: the hypothesis is still supported by scientists and scientific data. Am J Public Health 1997;87:689–690.
Cullen MR. The amphibole hypothesis of asbestos-related cancer—gone but not forgotten [editorial]. Am J Public Health 1996;86:158–159.
Stayner LT, Dankovic DA, Lemen RA. Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Am J Public Health 1996;86:179–186.
Stayner LT, Dankovic DA, Lemen RA. Asbestos-related cancer and the amphibole hypothesis: 2: Stayner and colleagues respond. Am J Public Health 1997;87:688.
Langer AMP, Nolan RPP. Asbestos-related cancer and the amphibole hypothesis: 3: The amphibole hypothesis: neither gone nor forgotten. Am J Public Health 1997;87:688–689.
Cullen MR. Asbestos-related cancer and the amphibole hypothesis: 5: Cullen responds. Am J Public Health 1997;87:690–691.
Stayner LT, Dankovic DA, Lemen RA. Asbestos-related cancer and the amphibole hypothesis: 6: Stayner and colleagues respond. Am J Public Health 1997;87:691.
McDonald AD, Case BW, Churg A, et al. Mesothelioma in Quebec chrysotile miners and millers: epidemiology and aetiology. Ann Occup Hyg 1997;41:707–719.
McDonald JC, McDonald AD. Chrysotile, tremolite and carcinogenicity. Ann Occup Hyg 1997;41:699–705.
Emri S, Demir A, Dogan M, et al. Lung diseases due to environmental exposures to erionite and asbestos in Turkey. Toxicol Lett 2002;127:251–257.
Coplu L, Dumortier P, Demir AU, et al. An epidemiological study in an Anatolian village in Turkey environmentally exposed to tremolite asbestos. J Environ Pathol Toxicol Oncol 1996;15:177–182.
Viallat JR, Boutin C, Steinbauer J, et al. Pleural effects of environmental asbestos pollution in Corsica. Ann NY Acad Sci 1991;643:438–443.
Goldberg P, Luce D, Billon-Galland MA, et al. Potential role of environmental and domestic exposure to tremolite in pleural cancer in New Caledonia [French]. Rev Epidemiol Santé Publique 1995;43:444–450.
Luce D, Bugel I, Goldberg P, et al. Environmental exposure to tremolite and respiratory cancer in New Caledonia: a case-control study. Am J Epidemiol 2000;151:259–265.
McDonald JC, McDonald AD, Armstrong B, Sebastien P. Cohort study of mortality of vermiculite miners exposed to tremolite. Br J Ind Med 1986;43:436–444.
Amandus HE, Wheeler R. The morbidity and mortality of vermiculite miners and millers exposed to tremoliteactinolite: part ii: mortality. Am J Ind Med 1987;11:15–26.
Case BW. Health effects of tremolite. Now and in the future. Ann NY Acad Sci 1991;643:491–504.
De Guire L, Labrèche F, Poulin M, Dionne M. The use of chrysotile asbestos in Quebec. Montreal, Quebec: Institut National de Santé Publique du Québec, 2005.
De Guire Le. The epidemiology of asbestos-related diseases in Quebec. Montreal, Québec: Institut National de Santé du Québec, 2004.
Yano E, Wang Z-M, Wang X-R, et al. Cancer mortality among workers exposed to amphibole-free chrysotile. Am J Epidemiol 2001;154:538–543.
Tossavainen A, Kovalevsky E, Vanhala E, Tuomi T. Pulmonary mineral fibers after occupational and environmental exposure to asbestos in the Russian chrysotile industry. Am J Ind Med 2000;37:327–333.
Tossavainen A, Kotilainen M, Takahashi K, et al. Amphibole fibres in Chinese chrysotile asbestos. Ann Occup Hyg 2001;45:145–152.
Williams-Jones AE, Normand C, Clark JR, et al. Controls of amphibole formation in chrysotile deposits: evidence from the Jeffrey Mine, Asbestos, Quebec. In: Nolan RP, Langer AM, Ross M, et al., eds. The health effects of chrysotile: contribution of science to risk-management decisions. Can Mineral 2001;spec publ 5:89–104.
Kashansky SV, Scherbakov SV, Kogan FM. Dust levels in workplace air (a retrospective view of “Uralasbest”). In: Peters GA, Peters BJ, eds. Sourcebook on asbestos diseases, vol. 15. Charlottesville: Lexis, 1997;15:337–354.
Scherbakov SV, Dommin SG, Kashansky SV. Dust levels in workplace air of the mines and mills of Uralasbest Company. In: Lehtinen S, Tossavainen A, Rantanen J, eds. Proceedings of the Asbestos Symposium for the Countries of Central and Eastern Europe, Budapest, December 1997. People and Work Research Reports 19. Helsinki: FIOH, 1998:104–108.
Kashansky SV. A 300-year history of the discovery of asbestos in the Urals. In: Peters GA, Peters BJ, eds. Sourcebook on asbestos diseases, vol. 20. Charlottesville: Lexis, 1999;20:129–144.
Kogan FM. Asbestos-related diseases in Russia. In: Banks DE, Parker JE, eds. Occupational lung disease: an international perspective. London: Chapman & Hall, 1998:247–253.
Vudrag M, Krajnc K. Asbestos in the Republic of Slovenia. In: Lehtinen S, Tossavainen A, Rantanen J, eds. Proceedings of the Asbestos Symposium for the Countries of Central and Eastern Europe, Budapest, December 1997. People and Work Research Reports 19. Helsinki: FIOH, 1998;19:79–84.
Tcherneva-Jalova P, Lukanova R, Demirova M. Asbestos in Bulgaria. In: Lehtinen S, Tossavainen A, Rantanen J, eds. Proceedings of the Asbestos Symposium for the Countries of Central and Eastern Europe, Budapest, December 1997. People and Work Research Reports 19. Helsinki: FIOH, 1998;19:33–38.
Indulski J, Szeszenia-Dabrowska N. Asbestos in Poland. In: Lehtinen S, Tossavainen A, Rantanen J, eds. Proceedings of the Asbestos Symposium for the Countries of Central and Eastern Europe, Budapest, December 1997. People and Work Research Reports 19. Helsinki: FIOH, 1998;19:55–62.
Sturm W, Menze B, Krause J, Thriene B. Use of asbestos, health risks and induced occupational diseases in the former East Germany. Toxicol Lett 1994;72:317–324.
Sturm W, Menze B, Krause J, Thriene B. Asbestos-related diseases and asbestos types used in the former GDR. Exp Toxicol Pathol 1995;47:173–178.
Yano E, Wang ZM, Wang XR, et al. Does exposure to chrysotile asbestos without amphibole cause lung cancer? Epidemiology for Sustainable Health: The XV International Scientific Meeting of the International Epidemiological Association, 1999;209.
Dement JM, Brown DP, Okun A. Follow-up study of chrysotile asbestos textile workers: cohort mortality and case-control analyses. Am J Ind Med 1994;26:431–447.
Dement JM, Brown DP. Lung cancer mortality among asbestos textile workers: a review and update. Ann Occup Hyg 1994;38:525–532.
Morinaga K, Kohyama N, Yokoyama K, et al. Asbestos fibre content of lungs with mesotheliomas in Osaka, Japan: a preliminary report. IARC Sci Publ 1989:438–443.
Yarborough CM. Chrysotile as a cause of mesothelioma: an assessment based on epidemiology. Crit Rev Toxicol 2006;36:165–187.
Paustenbach DJ, Finley BL, Lu ET, Brorby GP. Environmental and occupational health hazards associated with the presence of asbestos in brake linings and pads (1900 to present): a “state-of’-the-art” review. J Toxicol Environ Health [B] 2004;7:25–80.
Lorimer WV, Rohl AN, Miller A, et al. Asbestos exposure of brake repair workers in the United States. Mt Sinai J Med 1976;43:207–218.
Rohl AN, Langer AM, Wolff MS, Weisman I. Asbestos exposure during brake lining maintenance and repair. Environ Res 1976;12:110–128.
Huncharek M, Muscat J, Capotorto JV. Pleural mesothelioma in a brake mechanic. Br J Ind Med 1989;46:69–71.
Robinson C, Lemen R, Wagoner JK. Mortality patterns, 1940–1975, among workers employed in an asbestos textile friction and packing products manufacturing facility. In: Lemen R, Dement JM, eds. Dusts and diseases. Park Forest South, IL: Pathotox, 1979:131–143.
Berry G, Newhouse ML. Mortality of workers manufacturing friction materials using asbestos. Br J Ind Med 1983;40:1–7.
McDonald AD, Fry JS, Wooley AJ, Mcdonald JC. Dust exposure and mortality in an American chrysotile asbestos friction products plant. Br J Ind Med 1984;41:151–157.
Newhouse ML, Sullivan KR. A mortality study of workers manufacturing friction materials: 1941–1986. Br J Ind Med 1989;46:176–179.
Yeung P, Patience K, Apthorpe L, Willcocks D. An Australian study to evaluate worker exposure to chrysotile in the automotive service industry. Appl Occup Environ Hyg 1999;14:448–457.
Kohyama N. Airborne asbestos levels in nonoccupational environments in Japan. IARC Sci Publ 1989:262–276.
Kauppinen T, Korhonen K. Exposure to asbestos during brake maintenance of automotive vehicles by different methods. Am Ind Hyg Assoc J 1987;48:499–504.
Weir FW, Tolar G, Meraz LB. Characterization of vehicular brake service personnel exposure to airborne asbestos and particulate. Appl Occup Environ Hyg 2001;16:1139–1146.
Rödelsperger K, Jahn H, Brückel B, et al. Asbestos dust exposure during brake repair. Am J Ind Med 1986;10:63–72.
Butnor KJ, Sporn TA, Roggli VL. Exposure to brake dust and malignant mesothelioma: a study of 10 cases with mineral fiber analysis. Ann Occup Hyg 2003;47:325–330.
Dodson RF, Poye LW, Hammar SP. Asbestos burden in lung tissue from an individual with extensive exposure to brake dust. Submitted for publication 2007.
Goodman M, Teta MJ, Hessel PA, et al. Mesothelioma and lung cancer among motor vehicle mechanics: a meta-analysis. Ann Occup Hyg 2004;48:309–326.
Hessel PA, Teta MJ, Goodman M, Lau E. Mesothelioma among brake mechanics: an expanded analysis of a casecontrol study. Risk Analysis 2004;24:547–552.
Laden F, Stampfer MJ, Walker AM. Lung cancer and mesothelioma among male automobile mechanics. Rev Environ Health 2004;19:39–61.
Egilman DS, Billings MA. Abuse of epidemiology: automobile manufacturers manufacture a defense to asbestos liability. Int J Occup Environ Health 2005;11:360–371.
Egilman D, Bohme SR. Over a barrel: corporate corruption of science and its effects on workers and the environment. Int J Occup Environ Health 2005;11:331–337.
Gennaro V, Tomatis L. Business bias: how epidemiologic studies may underestimate or fail to detect increased risks of cancer and other diseases. Int J Occup Environ Health 2005;11:356–359.
Carel R, Boffetta P, Kauppinen T, et al. Exposure to asbestos and lung and pleural cancer mortality among pulp and paper industry workers. J Occup Environ Med 2002;44:579–584.
Henderson DW, de Klerk NH, Hammar SP, et al. Asbestos and lung cancer: is it attributable to asbestosis, or to asbestos fiber burden? In: Corrin B, ed. Pathology of lung tumors. New York: Churchill Livingstone, 1997:83–118.
Leigh J, Davidson P, Hendrie L, Berry D. Malignant mesothelioma in Australia, 1945–2000. Am J Ind Med 2002;41:188–201.
National Industrial Chemicals Notification and Assessment Scheme (NICNAS) (Australia). Full public report: chrysotile asbestos—priority existing chemical no. 9. NICNAS; National Occupational Health and Safety Commission (NOHSC). Sydney: Commonwealth of Australia, 1999.
Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965;58:295–300.
Popper K. The logic of scientific discovery. London: Routledge Classics (originally published as Logic der Forschung in Vienna: Verlag von Julius Springer 1935), 1959/2002.
Popper K. Conjectures and refutations: the growth of scientific knowledge. London: Routledge Classics, 1963/2002.
Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax 1999;54:638–652.
Bielefeldt-Ohlmann H, Jarnicki AG, Fitzpatrick DR. Molecular pathobiology and immunology of malignant mesothelioma. J Pathol 1996;178:369–378.
McLaren BR, Robinson BWS. The molecular pathogenesis of mesothelioma. In: Robinson BWS, Chahinian AP, eds. Mesothelioma. London: Martin Dunitz, 2002:307–323.
Ramos-Nino ME, Testa JR, Altomare DA, et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem 2006;98:723–734.
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307–310.
Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest 2004;125:1103–1117.
Manning CB, Vallyathan V, Mossman BT. Diseases caused by asbestos: mechanisms of injury and disease development. Int Immunopharmacol 2002;2:191–200.
Schins RP. Mechanisms of genotoxicity of particles and fibers. Inhal Toxicol 2002;14:57–78.
Hesterberg TW, Barrett JC. Induction by asbestos fibers of anaphase abnormalities: mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis 1985;6:473–475.
Dopp E, Schiffmann D. Analysis of chromosomal alterations induced by asbestos and ceramic fibers. Toxicol Lett 1998;96–97:155–162.
Oloffson K, Mark J. Specificity of asbestos-induces chromosomal abnormalities in short term cultured human mesothelial cells. Cancer Genet Cytogenet 1989;41:33–39.
Jaurand MC. Mechanisms of fiber-induced genotoxicity. Environ Health Perspect 1997;105:1073–1084.
Stanton MF, Layard M, Tegeris A, et al. Carcinogenicity of fibrous glass: pleural response in the rat in relation to fiber dimension. J Natl Cancer Inst 1977;58:587–603.
Kamp DW, Greenberger MJ, Sbalchierro JS, et al. Cigarette smoke augments asbestos-induced alveolar epithelial cell injury: role of free radicals. Free Radic Biol Med 1998;25:728–739.
Unfried K, Schurkes C, Abel J. Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo. Cancer Res 2002;62:99–104.
Fach E, Kristovich R, Long JF, et al. The effect of iron on the biological activities of erionite and mordenite. Environ Int 2003;29:451–458.
Ruotsalainen M, Hirvonen MR, Luoto K, Savolainen KM. Production of reactive oxygen species by man-made vitreous fibres in human polymorphonuclear leukocytes. Hum Exp Toxicol 1999;18:354–362.
Broaddus VC, Yang L, Scavo LM, et al. Crocidolite asbestos induces apoptosis of pleural mesothelial cells: role of reactive oxygen species and poly(ADP-ribosyl) polymerase. Environ Health Perspect 1997;105:1147–1152.
Kahlos K, Soini Y, Paakko P, et al. Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. Int J Cancer 2000;88:37–43.
Broaddus VC, Yang L, Scavo LM, et al. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest 1996;98:2050–2059.
Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol 1998;275:L165–171.
Janssen Y, Marsh J, Quinlan T, et al. Activation of early cellular responses by asbestos: induction of c-FOS and c-JUN protooncogene expression in rat pleural mesothelial cells. In: Davis JMG, Jaurand M-C, eds. Cellular and molecular effects of mineral and synthetic dusts and fibres. NATO ASI Series, H85. Berlin: Springer-Verlag; 1994:205–213.
Vintman L, Nielsen S, Berner A, et al. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 2005;103:2427–2433.
Appel JD, Fasy TM, Kohtz DS, et al. Asbestos fibers mediate transformation of monkey cells by exogenous plasmid DNA. Proc Natl Acad Sci USA 1988;85:7670–7674.
Tiainen M, Kere J, Tammilehto L, et al. Abnormalities of chromosomes 7 and 22 in human malignant pleural mesothelioma: correlation between Southern blot and cytogenetic analyses. Genes Chromosomes Cancer 1992;4:176–182.
Xio S, Li D, Vijg J, et al. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11:511–515.
Kivipensas P, Bjorkqvist AM, Karhu R, et al. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 1996;89:7–13.
Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21–p22 in malignant mesothelioma. Cancer Res 1994;54:5547–5551.
Both K, Turner DR, Henderson DW. Loss of heterozygosity in asbestos-induced mutations in a human mesothelioma cell line. Environ Mol Mutagen 1995;26:67–71.
Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma. Int J Oncol 1999;14:181–188.
Bjorkqvist AM, Wolf M, Nordling S, et al. Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer 1999;81:1111–1115.
Simon F, Johnen G, Krismann M, Muller KM. Chromosomal alterations in early stages of malignant mesotheliomas. Virchows Arch 2005;447:762–767.
Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227–1231.
Deguen B, Goutebroze L, Giovannini M, et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 1998;77:554–560.
Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995;92:10854–10858.
Kleymenova EV, Bianchi AA, Kley N, et al. Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma. Mol Carcinog 1997;18:54–60.
Gusella JF, Ramesh V, MacCollin M, Jacoby LB. Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta 1999;1423:M29–36.
Rihn B, Coulais C, Kauffer E, et al. Inhaled crocidolite mutagenicity in lung DNA. Environ Health Perspect 2000;108:341–346.
Papp T, Schipper H, Pemsel H, et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 2001;18:425–433.
Ni Z, Liu Y, Keshava N, et al. Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat Res 2000;468:87–92.
Yang CT, You L, Lin YC, et al. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res 2003;23:33–38.
Yang CT, You L, Uematsu K, et al. P14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001;61:5959–5963.
Yang CT, You L, Yeh CC, et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000;92:636–641.
Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998;16:3087–3095.
Ortega A, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73–87.
Baldi A, Groeger AM, Esposito V, et al. Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival. Thorax 2002;57:353–356.
Hirvonen A, Mattson K, Karjalainen A, et al. Simian virus 40 (SV40)-like DNA sequences not detectable in Finnish mesothelioma patients not exposed to SV40-contaminated polio vaccines. Mol Carcinog 1999;26:93–99.
Pilatte Y, Vivo C, Renier A, et al. Absence of SV40 large T-antigen expression in human mesothelioma cell lines. Am J Respir Cell Mol Biol 2000;23:788–793.
Carbone M, Rizzo P, Powers A, et al. Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications. Anticancer Res 2002;22:3443–3448.
Carbone M, Rizzo P, Procopio A, et al. SV40-like sequences in human bone tumors. Oncogene 1996;13:527–535.
Butel JS, Lednicky JA, Stewart AR, et al. SV40 and human brain tumors. J Neurovirol 1997;1:S78–79.
Strickler HD, Rosenberg PS, Devesa SS, et al. Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates. JAMA 1998;279:292–295.
Olin P, Giesecke J. Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960 to 1993. Dev Biol Stand 1998;94:227–233.
Shah KV. SV40 and human cancer: a review of recent data. Int J Cancer 2006;120:215–223.
Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 1993;142:1524–1533.
Ke Y, Reddel RR, Gerwin BI, et al. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol 1989;134:979–991.
Wang Y, Faux SP, Hallden G, et al. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol 2004;25:173–178.
Whitson BA, Kratzke RA. Molecular pathways in malignant pleural mesothelioma. Cancer Lett 2006;239:183–189.
Strizzi L, Vianale G, Giuliano M, et al. SV40, JC and BK expression in tissue, urine and blood samples from patients with malignant and nonmalignant pleural disease. Anticancer Res 2000;20:885–889.
Catalano A, Romano M, Martinotti S, Procopio A. Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene 2002;21:2896–2900.
Mossman BT, Gruenert DC. SV40, growth factors, and mesothelioma: another piece of the puzzle. Am J Respir Cell Mol Biol 2002;26:167–170.
Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468–475.
Kumar P, Kratzke RA. Molecular prognostic markers in malignant mesothelioma. Lung Cancer 2005;49:S53–60.
Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF beta expression. J Pathol 1999;189:72–78.
Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209–225.
Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341–347.
Thorner P, Squire J, Plavsic N, et al. Expression of WT1 in pediatric small cell tumors: report of two cases with a possible mesothelial origin. Pediatr Dev Pathol 1999;2:33–41.
Hoffmann R, Valencia A. A gene network for navigating the literature. Nature Genet 2004;36:664.
Maheswaran S, Park S, Bernard A, et al. Physical and functional interaction between Wt1 and p53 proteins. Proc Natl Acad Sci USA 1993;90:5100–5104.
Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 1997;181:67–74.
Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2–17.
Xiao GH, Beeser A, Chernoff J, Testa JR. P21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002;277:883–886.
Knudson A. Asbestos and mesothelioma: genetic lessons from a tragedy. Proc Natl Acad Sci USA 1995;92:10819–10820.
Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997;57:2121–2123.
Nelson HH, Wiencke JK, Gunn L, et al. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998;58:1804–1807.
Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999;17:1618–1624.
Cai YC, Roggli V, Mark E, et al. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med 2004;128:68–70.
Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 2006;51:207–215.
Cesario A, Catassi A, Festi L, et al. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. Clin Cancer Res 2005;11:2026–2037.
Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 1996;56:5334–5338.
Walker C, Everitt J, Ferriola PC, et al. Autocrine growth stimulation by transforming growth factor alpha in asbestos-transformed rat mesothelial cells. Cancer Res 1995;55:530–536.
Faux SP, Houghton CE, Hubbard A, Patrick G. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. Carcinogenesis 2000;21:2275–2280.
Pache JC, Janssen YM, Walsh ES, et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol 1998;152:333–340.
Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002;62:5242–5247.
Liu Z, Klominek J. Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. Neoplasia 2004;6:705–712.
Mukohara T, Civiello G, Johnson BE, Janne PA. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology 2005;68:500–510.
She Y, Lee F, Chen J, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 2003;9:3773–3778.
Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003;63:1–5.
Govindan R, Kratzke RA, Herndon JE, 2nd, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11:2300–2304.
Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of singleagent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59:149–150.
Baldi A, Santini D, Vasaturo F, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004;59:428–433.
Cardillo I, Spugnini EP, Verdina A, et al. Cox and mesothelioma: an overview. Histol Histopathol 2004;20:1267–1274.
Edwards JG, Faux SP, Plummer SM, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002;8:1857–1862.
O’Kane SL, Cawkwell L, Campbell A, Lind MJ. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer 2005;41:1645–1648.
Edwards JG, Swinson DE, Jones JL, et al. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006;54:399–407.
Marrogi A, Pass HI, Khan M, et al. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000;60:3696–3700.
Catalano A, Graciotti L, Rinaldi L, et al. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 2004;109:322–328.
Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54–61.
Konig JE, Tolnay E, Wiethege T, Muller KM. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Archiv 1999;435:8–12.
Demirag F, Unsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005;128:3382–3387.
Aoe K, Hiraki A, Tanaka T, et al. Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res 2006;26:4833–4836.
Konig J, Tolnay E, Wiethege T, Muller K. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 2000;67:36–40.
Masood R, Kundra A, Zhu ST, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003;104:603–610.
Cacciotti P, Strizzi L, Vianale G, et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2002;26:189–193.
Partanen R, Koskinen H, Hemminki K. Tumour necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer. Occup Environ Med 1995;52:316–319.
Yang H, Bocchetta M, Kroczynska B, et al. TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006;103:10397–10402.
Donaldson K, Li XY, Dogra S, et al. Asbestos-stimulated tumour necrosis factor release from alveolar macrophages depends on fibre length and opsonization. J Pathol 1992;168:243–248.
Falleni M, Pellegrini C, Marchetti A, et al. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer 2005;48:211–216.
Gordon G, Mani M, Mukhopadhyay L, et al. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007;211:447–454.
Gordon G, Mani M, Mukhopadhyay L, et al. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 2007;211:439–446.
Liu Z, Ivanoff A, Klominek J. Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer 2001;91:638–643.
Zhong J, Gencay MM, Bubendorf L, et al. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol 2006;207:540–552.
Hirano H, Tsuji M, Kizaki T, et al. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study. Med Electron Microsc 2002;35:16–23.
Edwards JG, McLaren J, Jones JL, et al. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 2003;88:1553–1559.
Liu Z, Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax 2003;58:198–203.
Hoang CD, D’Cunha J, Kratzke MG, et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004;125:1843–1852.
Versnel MA, Hagemeijer A, Bouts MJ, et al. Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cells lines derived from primary and metastatic tumors. Oncogene 1988;2:601–605.
Versnel MA, Claesson-Welch L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF β-receptors whereas cultured normal mesothelial cells express predominantly PDGF α-receptors. Oncogene 1991;6:2005–2011.
Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 1992;9:151–161.
Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998;110:397–404.
Whitaker D, Papadimitriou JM, Walters MN-I. The mesothelium and its reactions: a review. CRC Crit Rev Toxicol 1982;10:81–144.
Whitaker D, Papadimitriou JM. Mesothelial healing: morphological and kinetic investigations. J Pathol 1985;145:159–175.
Whitaker D, Manning LS, Robinson BW, Shilkin KB. The pathobiology of the mesothelium. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992:25–68.
Mutsaers SE, Whitaker D, Papadimitriou J. Stimulation of mesothelial healing by exudate macrophages enhances serosal wound healing in a murine model. Am J Pathol 2002;160:680–692.
Whitaker D. The mesothelium of the rat and its response to injury. Thesis, University of Western Australia, 1983.
Catalano A, Romano M, Robuffo I, et al. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol 2001;159:721–731.
McCaughey WTE. Criteria for the diagnosis of diffuse mesothelial tumors. Ann NY Acad Sci 1965;132:603–613.
Kannerstein M, McCaughey WEE, Churg J, Selikoff IJ. A critique for the diagnosis of diffuse malignant mesothelioma. Mt Sinai J Med (NY) 1977;44:485–494.
Kannerstein M, Churg J, McCaughey WTE. Asbestos and mesothelioma: a review. Pathol Annu 1978:81–130.
Adams VI, Unni KK. Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study. Am J Clin Pathol 1984;82:15–23.
McCaughey WTE, Kannerstein M, Churg J. Tumors of the serous membranes. Washington, DC: Armed Forces Institute of Pathology, 1985.
Battifora H, McCaughey WTE. Tumors of the serosal membranes. Washington, DC: Armed Forces Institute of Pathology, 1994.
Churg A, Cagle PT, Roggli VL. Tumors of the Serosal Membranes. Washington DC: American Registry of Pathology/Armed Forces Institute of Pathology, 2006.
Hammar SP, et al. Round cell mesotheliomas with an emphasis on deciduoid mesothelioma. Submitted for publication.
Hammar SP, Bockus DE, Remington FL, Rohrbach KA. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultra Pathol 1996;20:293–325.
Ordóñez NG, Myhre M, Mackay B. Clear cell mesothelioma. Ultrastruct Pathol 1996;20:331–336.
Sporn TA, Roggli VL. Mesothelioma. In: Roggli VL, Oury TD, Sporn TA, eds. Pathology of asbestos-associated diseases, 2nd ed. New York: Springer, 2004:104–168.
Mayall FG, Goddard H, Gibbs AR. Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon. Histopathology 1992;21:453–457.
Battifora H. Leiomyoid mesotheliomas [letter]. Histopathology 1993;21:601.
Churg A, Roggli V, Galateau-Sallé F, et al. Mesothelioma. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris C, eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC, 2004:128–136.
Attanoos RL, Dojcinov SD, Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000;37:224–231.
Hinterberger M, Reineke T, Storz M, et al. D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol 2007;20:248–255.
Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000;24:1183–1200.
Montag AG, Pinkus GS, Corson JM. Keratin protein immunoreactivity of sarcomatoid and mixed types of diffuse malignant mesothelioma: an immunoperoxidase study of 30 cases. Hum Pathol 1988;19:336–342.
Battifora H. The pleura. In: Sternberg SS, ed. Diagnostic surgical pathology. New York: Raven Press, 1989:829–855.
Roggli VL, Kolbeck J, Sanfilippo F, Shelburne JD. Pathology of human mesothelioma: etiologic and diagnostic considerations. Pathol Annu 1987;22:91–131.
McCaughey WTE, Dardick I, Barr JR. Angiosarcoma of serous membranes. Arch Pathol Lab Med 1983;107:304–307.
Falconieri G, Bussani R, Mirra M, Zanella M. Pseudomesotheliomatous angiosarcoma: a pleuropulmonary lesion simulating malignant pleural mesothelioma. Histopathology 1997;30:419–424.
Zhang PJ, Livolsi VA, Brooks JJ. Malignant epithelioid vascular tumors of the pleura: report of a series and literature review. Hum Pathol 2000;31:29–34.
Yousem SA, Hochholzer L. Malignant mesotheliomas with osseous and cartilaginous differentiation. Arch Pathol Lab Med 1987;111:62–66.
Gaertner E, Zeren EH, Fleming MV, et al. Biphasic synovial sarcomas arising in the pleural cavity: a clinicopathologic study of five cases. Am J Surg Pathol 1996;20:36–45.
Jawahar DA, Vuletin JC, Gorecki P, et al. Primary biphasic synovial sarcoma of the pleura. Respir Med 1997;91:568–570.
Nicholson AG, Goldstraw P, Fisher C. Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases. Histopathology 1998;33:508–513.
Caliandro R, Terrier P, Regnard JF, et al. Primary biphasic synovial sarcoma of the pleura [Fr]. Rev Mal Respir 2000;17:498–502.
Cappello F, Barnes L. Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis. Pathology 2001;33:142–148.
Bégueret H, Galateau-Sallé F, Guillou L, et al. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. Am J Surg Pathol 2005;29:339–346.
Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 2001;25:610–617.
Dos Santos NR, de Bruijn DR, Balemans M, et al. Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins. Hum Mol Genet 1997;6:1549–1558.
De Leeuw B, Balemans M, Olde Weghuis D, Geurts van Kessel A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet 1995;4:1097–1099.
Brett D, Whitehouse S, Antonson P, et al. The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 1997;6:1559–1564.
Argani P, Zakowski MF, Klimstra DS, et al. Detection of the SYT-SSX chimeric RNA of synovial sarcoma in paraffin-embedded tissue and its application in problematic cases. Mod Pathol 1998;11:65–71.
Mayall FG, Gibbs AR. “Pleural” and pulmonary carcinosarcomas. J Pathol 1992;167:305–311.
Colby TV, Koss MN, Travis WD. Tumors of the lower respiratory tract. Washington, DC: Armed Forces Institute of Pathology, 1995.
Travis WD, Colby TV, Corrin B. Histological typing of lung and pleural tumours, 3rd ed. Berlin: Springer, 1999.
Hansen T, Bittinger F, Kortsik C, et al. Expression of KIT (CD117) in biphasic pulmonary blastoma: novel data on histogenesis. Lung 2003;181:193–200.
Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue: a light-microscopic, ultrastructural and immunocytochemical study. Am J Surg Pathol 1986;10:34–47.
Dardick I, Al-Jabi M, McCaughey WTE, Srigley JR, van Nostrand AWP, Ritchie AC. Ultrastructure of poorly differentiated diffuse epithelial mesotheliomas. Ultrastruct Pathol 1984;7:151–160.
Cook HC. Carbohydrates. In: Bancroft JD, Stevens A, eds. Theory and practice of histological techniques. New York: Churchill Livingstone, 1982:180–216.
MacDougall DB, Wang SE, Zibar BL. Mucin-positive epithelial mesothelioma. Arch Pathol Lab Med 1992;116:874–880.
Friedman HD, Litovsky SH, Abraham JL. Mucin-positive epithelial mesothelioma and pseudomesotheliomatous adenocarcinoma [letter; comment]. Arch Pathol Lab Med 1993;117:967.
Battifora H. Mesothelioma versus carcinoma: getting easier? Hum Pathol 2005;36:1153.
King JE, Galateau-Sallé F, Hasleton P. Histopathology of malignant pleural mesothelioma. In: O’Byrne K, Rusch V, eds. Malignant pleural mesothelioma. Oxford: Oxford University Press, 2006:61–103.
Bedrossian CWM, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol 1992;9:124–140.
Betta P. Immunohistochemistry. In: Pass H, Vogelzang NJ, Carbone M, eds. Malignant mesothelioma. New York: Springer, 2005:490–507.
Coleman M, Henderson DW, Mukherjee TM. The ultrastructural pathology of malignant pleural mesothelioma. Pathol Annu 1989;24:303–353.
Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histologic mimics: a comparative immunohistochemical study. Histopathology 2003;42:270–279.
King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006;48:223–232.
Lumb PD, Suvarna SK. Metastasis in pleural mesothelioma: immunohistochemical markers for disseminated disease. Histopathology 2004;44:345–352.
Beer TW, Buchanan R, Matthews AW, et al. Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 1998;29:246–251.
Comin CE, Anichini C, Boddi V, et al. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathology 2000;36:26–31.
Leonardo E, Zanconati F, Bonifacio D, Bonito LD. Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma. Pathol Res Pract 2001;197:253–256.
Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura: analysis of markers. Mod Pathol 2004;17:476–481.
Bongiovanni M, Cassoni P, De Giuli P, et al. P27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001;92:1245–1250.
Beer TW, Shepherd P, Pullinger NC. P27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001;38:535–541.
Betta PG, Andrion A, Donna A, et al. Malignant mesothelioma of the pleura: the reproducibility of the immunohistological diagnosis. Pathol Res Pract 1997;193:759–765.
Chang K, Pai HL, Batra J, et al. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 that is present on ovarian cancers and normal mesothelium. Cancer Res 1992;52:181–186.
Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259–268.
O’Hara CJ, Corson JM, Pinkus GS, et al. ME1 a monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol 1990;136:421–428.
Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002;55:662–668.
Simsir A, Fetsch P, Mehta D, et al. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol 1999;20:125–130.
Wieczorek TJ, Krane JF. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer 2000;90:312–319.
Kitazume H, Kitamura K, Mukai K, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 2000;90:55–60.
Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006;19:514–523.
Ordóñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203–1214.
Roberts F, McCall AE, Burnett RA. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry. J Clin Pathol 2001;54:766–770.
Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001;25:158–161.
Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002;40:237–244.
Ordóñez NG. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399–1408.
Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409–1419.
Wick MR. Immunophenotyping of malignant mesothelioma. Am J Surg Pathol 1997;21:1395–1398.
Zimmerman RL. There’s madness in the methods. Diagn Cytopathol 2005;32:183–184.
Fetsch P, Simsir A, Abati A. There may be “madness in the methods” but the devil is in the detail. Diagn Cytopathol 2005;34:590–593.
Zimmerman RL. Response to Dr. Abati’s letter to the editor. Diagn Cytopathol 2005;34:594–595.
Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis. APMIS 1994;102:255–264.
Brockstedt U, Gulyas M, Dobra K, et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000;114:203–209.
Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000;11:8–17.
Carella R, Deleonardi G, D’Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001;25:43–50.
Ordóñez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999;30:313–323.
Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031–1051.
Ordóñez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005;129:1407–1414.
Ordóñez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007;38:1–16.
Frisman DM. Immunoquery. 2006. http://www.ipox.org/login.cfm?IQMessage=1&RequestTimeout=200.
Butnor KJ, Sporn TA, Ordóñez NG. Recommendations for the reporting of pleural mesothelioma. Hum Pathol 2007;450:15–23.
Billing-Marczak K, Kuznicki J. Calretinin—sensor or buffer-function still unclear. Pol J Pharmacol 1999;51:173–178.
Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type [published erratum appears in Pathol Res Pract 1996;192:646]. Pathol Res Pract 1996;192:137–147.
Tos AP, Doglioni C. Calretinin: a novel tool for diagnostic immunohistochemistry. Adv Anat Pathol 1998;5:61–66.
Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037–1046.
Comin CE, Novelli L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001;32:529–536.
Ordóñez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002;33:953–967.
Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997;31:140–143.
Ordóñez NG. Value of cytokeratin5/6 in distinguishing epithelial mesothelioma of pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215–1221.
Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15:6–10.
Bateman AC, Al-Talib RK, Newman T, et al. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1. Histopathology 1997;30:49–56.
Renshaw AA, Pinkus GS, Gorson JM. HBME-1 aids in distinguishing mesotheliomas and adenocarcinomas of the lung and breast. Mod Pathol 1995;8:152A.
Gonzalez-Lois C, Ballestin C, Sotelo MT, et al. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528–534.
Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316–1320.
Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 2003;199:479–487.
Amin KM, Litzky LA, Smythe WR, et al. Wilms’ tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344–356.
Hecht JL, Lee BH, Pinkus JL, Pinkus GS. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer 2002;96:105–109.
Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004;35:697–710.
Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913–921.
Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105–110.
Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372–380.
Muller AM, Franke FE, Muller KM. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Pathobiology 2006;73:50–54.
Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol 2006;30:878–882.
Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827–833.
Collins CL, Fink LM, Hsu S-M, et al. Thrombomodulin staining of mesothelioma cells [letter]. Hum Pathol 1992;23:966.
Fink L, Collins CL, Schaefer R, et al. Thrombomodulin expression can be used to differentiate between mesotheliomas and adenocarcinomas. Lab Invest 1992;66:113A.
Cury PM, Butcher DN, Fisher C, et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107–112.
Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373–381.
Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27:150–158.
Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192–197.
Galloway ML, Murray D, Moffat DF. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies. Histopathology 2006;48:767–769.
Kachali C, Eltoum I, Horton D, Chhieng DC. Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol 2006;23:20–24.
Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreatobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838–845.
Penno MB, Askin FB, Ma H, et al. High CD44 expression on human mesotheliomas mediates association with hyaluronan. Cancer J Sci Am 1995;1:196.
Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies. Am J Clin Pathol 2001;116:253–262.
Battifora HA, Gown AM. Do we need two more mesothelial markers? Hum Pathol 2005;36:451–452.
Wang N-S, Huang S-N, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers. Cancer 1979;44:937–943.
Dejmek A, Hjerpe A. Carcinoembryonic antigen-like reactivity in malignant mesothelioma: a comparison between different commercially available antibodies. Cancer 1994;73:464–469.
Robb JA. Mesothelioma versus adenocarcinoma: false-positive CEA and Leu-M1 staining due to hyaluronic acid [letter]. Hum Pathol 1989;20:400.
Johnson BL, Lee I, Gould VE. Epidemiology, pathogenesis, and pathology. In: Kittle CF, ed. Mesothelioma: diagnosis and management. Chicago: Year Book Medical Publishers, 1987:1–29.
Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: an immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986;123:212–219.
Sheibani K, Battifora H, Burke JS, Rappaport H. Leu-M1 antigen in human neoplasms: an immunohistologic study of 400 cases. Am J Surg Pathol 1986;10:227–236.
Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209–216.
Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989;13:276–291.
Wick MR, Loy T, Mills SE, et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990;21:759–766.
Attanoos RL, Goddard H, Thomas ND, et al. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Histopathology 1995;27:361–366.629.
Ordóñez NG. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases. Mod Pathol 2006;19:373–383.
Jordan DA, Jagirdar J, Kaneko M. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931–938.
Ordóñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44H immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598–606.
Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 2006;19:417–428.
Balzar M, Winter M, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699–712.
Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 2003;63:2139–2148.
De Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999;188:201–206.
Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818–5824.
Li Q, Bavikatty N, Michael CW. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion. Semin Diagn Pathol 2006;23:15–19.
Kortsik CS, Werner P, Freudenberg N, et al. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3—a new tumor marker. Lung 1995;173:79–87.
Robinson RJ, Royston D. Comparison of monoclonal antibodies AUA1 and BER EP4 with anti-CEA for detecting carcinoma cells in serous effusions and distinguishing them from mesothelial cells. Cytopathology 1993;4:267–271.
Chenard-Neu MP, Kabou A, Mechine A, et al. Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma: evaluation of 5 new antibodies and 6 traditional antibodies [Fr]. Ann Pathol 1998;18:460–465.
Soosay GN, Griffiths M, Papadaki L, et al. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. J Pathol 1991;163:299–305.
Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986;122:252–260.
Otis CN, Carter D, Cole S, Battifora H. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma: a bi-institutional study of 47 cases. Am J Surg Pathol 1987;11:445–456.
Ordóñez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma: review and update. Am J Clin Pathol 1999;112:75–89.
Skov BG, Lauritzen AF, Hirsch FR, et al. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies. Histopathology 1994;25:431–437.
Muller AM, Weichert A, Muller KM. E-cadherin, Eselectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma? Virchows Arch 2002;441:41–46.
Soler AP, Knudsen KA, Jaurand MC, et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995;26:1363–1369.
Bingle CD. Thyroid transcription factor-1. Int J Biochem Cell Biol 1997;29:1471–1473.
Minoo P, Hamdan H, Bu D, et al. TTF-1 regulates lung epithelial morphogenesis. Dev Biol 1995;172:694–698.
Lazzaro D, Price M, de Felice M, Di Lauro R. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 1991;113:1093–1104.
Stahlman MT, Gray ME, Whitsett JA. Expression of thyroid transcription factor-1 (TTF-1) in fetal and neonatal human lung. J Histochem Cytochem 1996;44:673–678.
Fabbro D, Di Loreto C, Stamerra O, et al. TTF-1 gene expression in human lung tumours. Eur J Cancer 1996;32A:512–517.
Holzinger A, Dingle S, Bejarano PA, et al. Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Hybridoma 1996;15:49–53.
Di Loreto C, Puglisi F, Di Lauro V, et al. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett 1998;124:73–78.
Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol 1998;42:1382–1388.
Puglisi F, Barbone F, Damante G, et al. Prognostic value of thyroid transcription factor-1 in primary, resected, nonsmall cell lung carcinoma. Mod Pathol 1999;12:318–324.
Afify AM, al-Khafaji BM. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol 2002;46:675–678.
Ng WK, Chow JC, Ng PK. Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens. Cancer 2002;96:43–48.
Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch 2002;440:353–361.
Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34βE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004;122:884–893.
Khoor A, Whitsett JA, Stahlman MT, et al. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 1999;30:695–700.
Henderson DW, Whitaker D, Shilkin KB. The differential diagnosis of mesothelioma: a practical approach to diagnosis during life. In: Henderson D, Shilkin K, Langlois SL, Whitaker D, eds. Malignant Mesothelioma. New York: Hemisphere, 1992:183–197.
Singh HK, Silvermann JF, Berns L, Haddad MG. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 2005;32:156–159.
Esteban JM, Yokota S, Husain S, Battifora H. Immunocytochemical profile of benign and carcinomatous effusions: a practical approach to difficult diagnosis. Am J Clin Pathol 1990;94:698–705.
Cury PM, Butcher DN, Corrin B, Nicholson AG. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 1999;189:251–257.
Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005;32:160–166.
Leong AS-Y, Parkinson R, Milios J. “Thick” cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma. Diagn Cytopathol 1990;6:9–13.
King JA, Tucker JA. Evaluation of membranous staining of mesothelioma. Cell Vis 1998;5:24–27.
Hammar SP, Bolen JW, Bockus D, et al. Ultrastructural and immunohistochemical features of common lung tumors: an overview. Ultrastruct Pathol 1985;9:283–318.
Krismann M, Thattamparambil P, Simon F, Johnen G. Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings. Pathologe 2006;27:99–105.
Saad RS, Cho P, Yulin LL, Silverman JF. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 2005;32:156–159.
Whitaker D, Shilkin KB, Sterrett GF. Cytological appearances of malignant mesothelioma. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992:167–182.
Walts AE, Said JW, Shintaku IP. Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: immunocytochemical and ultrastructural localization in benign and malignant cells. Diagn Cytopathol 1987;3:41–49.
Van der Kwast TH, Versnel MA, Delahaye M, et al. Expression of epithelial membrane antigen on malignant mesothelioma cells: an immunocytochemical and immunoelectron microscopic study. Acta Cytol 1988;32:169–174.
Lauritzen AF. Distinction between cells in serous effusions using a panel of antibodies. Virchows Arch A Path Anat Histopathol 1987;411:299–304.
Mason MR, Bedrossian CW, Fahey CA. Value of immunocytochemistry in the study of malignant effusions. Diagn Cytopathol 1987;3:215–221.
Silverman JF, Nance K, Phillips B, Norris HT. The use of immunoperoxidase panels for the cytologic diagnosis of malignancy in serous effusions. Diagn Cytopathol 1987;3:134–140.
Whitaker D, Sterrett G, Shilkin K. Early diagnosis of malignant mesothelioma: the contribution of effusion and fine needle aspiration cytology and ancillary techniques. In: Peters GA, Peters BJ, eds. Asbestos disease update March 1989: a special supplement to the sourcebook on asbestos diseases: medical, legal, and engineering aspects. New York: Garland Law Publishing, 1989:73–112.
Wolanski KD, Whitaker D, Shilkin KB, Henderson DW. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 1998;82:583–590.
Kushitani K, Takeshima Y, Amatya VJ, et al. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 2007;57:190–199.
Zhu W, Michael CW. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007;35:370–375.
Hedman M, Arnberg H, Wernlund J, et al. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 2003;23:531–536.
Kebapci M, Vardarell E, Adapinar B, Acikalin M. CT findings and serum CA 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003;13:2620–2626.
Baratti D, Kusamura S, Martinetti A, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2007;14:500–508.
Fleming MV, Guinee DG Jr, Chu WS, et al. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol 1998;29:60–64.
Navratil E, Gaulard P, Kanavaros P, et al. Expression of the bcl-2 protein in B cell lymphomas arising from mucosa associated lymphoid tissue. J Clin Pathol 1995;48:18–21.
Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994;145:1036–1040.
Segers K, Ramael M, Singh SK, et al. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 1994;424:631–634.
Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003;43:231–238.
King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006;49:561–568.
Ramael M, Lemmens G, Eerdekens C, et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992;168:371–375.
Mayall FG, Goddard H, Gibbs AR. The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos-associated mesotheliomas. Histopathology 1993;22:383–386.
Mullick SS, Green LK, Ramzy I, et al. P53 gene product in pleural effusions: practical use in distinguishing benign from malignant cells. Acta Cytol 1996;40:855–860.
Cagle PT, Brown RW, Lebovitz RM. P53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol 1994;25:443–448.
Esposito V, Baldi A, De Luca A, et al. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res 1997;17:733–736.
Mayall F, Heryet A, Manga D, Kriegeskotten A. P53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology. Cytopathology 1997;8:9–12.
Schneider J, Presek P, Braun A, et al. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer 1999;80:1987–1994.
Isik R, Metintas M, Gibbs AR, et al. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir Med 2001;95:588–593.
Kettunen E, Nicholson AG, Nagy B, et al. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis 2005;26:17–25.
Lantuéjoul S, Laverriere MH, Sturm N, et al. NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas. Hum Pathol 2000;31:415–421.
Ramaekers FCS, Haag D, Kant A, et al. Coexpression of keratin-and vimentin-type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci USA 1983;80:2618–2622.
Scoones DJ, Richman PI. Expression of desmin and smooth muscle actin in mesothelial hyperplasia and mesothelioma. J Pathol 1993;169:166A.
Dai Y, Bedrossian CW, Michael CW. The expression pattern of β-catenin in mesothelial proliferative lesions and its diagnostic utilities. Diagn Cytopathol 2005;33:320–324.
Wu M, Yuan S, Szporn AH, et al. Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol 2005;18:1618–1622.
Soini Y, Jarvinen K, Kaarteenaho-Wiik R, Kinnula V. The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 2001;12:1239–1245.
Ramael M, van den Bossche J, Buysse C, et al. Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. J Pathol 1992;167:5–8.
Afify A, Zhou H, Howell L, Paulino AF. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Acta Cytol 2005;49:621–626.
Okamoto H, Matsuno Y, Noguchi M, et al. Malignant pleural mesothelioma producing chorionic gonadotropin: report of two cases. Am J Surg Pathol 1992;16:969–974.
McAuley P, Asa SL, Chiv B, et al. Parathyroid hormonelike peptide in normal and neoplastic mesothelial cells. Cancer 1990;66:1975–1979.
Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962–972.
Butnor KJ, Nicholson AG, Allred DC, et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 2006;130:823–827.
Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer 2001;92:2727–2732.
Campbell F, Herrington CS. Application of cytokeratin 7 and 20 immunohistochemistry to diagnostic pathology. Curr Diagn Pathol 2001;7:113–122.
Saad RS, Lindner JL, Lin X, et al. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn Cytopathol 2006;34:801–806.
Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823–830.
Shieh S, Grassi M, Schwarz JK, Cheney RT. Pleural mesothelioma with cutaneous extension to chest wall scars. J Cutan Pathol 2004;31:497–501.
Ormsby AH, Snow JL, Su WP, Goellner JR. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein. J Am Acad Dermatol 1995;32:711–716.
Barnetson RJ, Burnett RA, Downie I, et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006;125:67–76.
Kafiri G, Thomas DM, Shepherd NA, et al. p53 expression is common in malignant mesothelioma. Histopathology 1992;21:331–334.
Suzuki Y, Churg J, Kannerstein M. Ultrastructure of human malignant diffuse mesothelioma. Am J Pathol 1976;85:241–262.
Klima M, Bossart MI. Sarcomatous type of malignant mesothelioma. Ultrastruct Pathol 1983;4:349–358.
d’Andiran G, Gabbiani G. A metastasizing sarcoma of the pleura composed of myofibroblasts. In: Fenoglio CM, Wolff M, eds. Progress in surgical pathology. New York: Mason, 1980:31–40.
Warhol MJ, Hickey WF, Corson JM. Malignant me sothelioma: ultrastructural distinction from adenocarcinoma. Am J Surg Pathol 1982;6:307–314.
Warhol MJ, Corson JM. An ultrastructural comparison of mesotheliomas with adenocarcinomas of the lung and breast. Hum Pathol 1985;16:50–55.
Burns TR, Greenberg SD, Mace ML, Johnson EH. Ultrastructural diagnosis of epithelial malignant mesothelioma. Cancer 1985;56:2036–2040.
Burns TRI, Johnson EH, Cartwright UR, Greenberg SD. Desmosomes of epithelial malignant mesothe lioma. Ultra Pathol 1988;12:385–388.
Tiainen M, Tammilethol L, Rautonen J, Tumoi T, Mattson K, Knoutila S. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 1989;60:618–626.
Hagemeijer A, Versnel MA, Van Drunen E, et al. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 1990;47:1–28.
Hicks J. Biologic, cytogenetic, and molecular factors in mesothelial proliferations. Ultrastruct Pathol 2006;30:19–30.
Davidson B, Holth A, Dong HP, et al. Chemokine receptors are rarely expressed on malignant or benign mesothelial cells. Lung Cancer 2006;54(S1):S14.
Jaurand MC. Asbestos, chromosomal deletions and tumor suppressor gene alterations in human malignant mesothelioma. Lung Cancer 2006;54(S1):S15.
Janne PA. Proteomic methods to identify novel therapeutic targets in malignant mesothelioma. Lung Cancer 2006;54(S1):S15.
Christensen JC, Marsit CJ, Nelson HH, et al. Asbestos burden, epigenetic silencing, and survival in malignant pleural mesothelioma. Lung Cancer 2006;54(S1):S21.
Rihn BH. Oxidative stress gene modulation in pleural mesothelioma as assessed by microarray in vitro, ex-vivo, and in-situ analysis. Lung Cancer 2006;54(S1):S21.
Bahnassy AA, Gaafar RM, Zekri AN, et al. Alterations of the G1 checkpoints in malignant pleural mesothelioma (MPM) in relation to pathogenesis and survival. Lung Cancer 2006;54(S1):S23.
Croonen AM, van der Valk P, Herman CJ, Lindeman J. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions. Lab Invest 1988;58:725–732.
Hafiz MA, Becker RL Jr, Mikel UV, Bahr GF. Cytophotometric determination of DNA in mesotheliomas and reactive mesothelial cells. Anal Quant Cytol Histol 1988;58:120–126.
Frierson HF, Mills SE, Legier JF. Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant mesothelioma. Am J Clin Pathol 1988;90:240–243.
Burmer GC, Rabinovitch PS, Kulander BG, Rusch V, McNutt MA. Flow cytometric analysis of malignant pleural mesothelioma: relationship to histology and survival. Hum Pathol 1989;20:777–783.
Dazzi H, Thatcher N, Hasleton PS, Chattlerjee AK, Lawson AM. DNA analysis by flow cytometry in malignant pleural mesothelioma: relationship to histology and survival. J Pathol 1990;162:51–55.
Tierney G, Wilkinson MJ, Jones JSP. The malignancy grading method is not a reliable assessment of malignancy in mesothelioma. J Pathol 1990;160:209–211.
El-Naggar AK, Ordone NG, Garnsey L, Batsakis JG. Epithelioid pleural mesotheliomas and pulmonary ad enocarcinomas: a comparative DNA flow cytometric study. Hum Pathol 1991;22:972–978.
Esteban JM, Sheibani K. DNA ploidy analysis of pleural mesotheliomas: Its usefulness for their distinction from lung adenocarcinomas. Mod Pathol 1992;6:626–630.
Cakir C, Gulluoglu MG, Yilmazbayhan D. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology 2006;38:10–15.
Kim BS, Varkey B, Choi H. Diagnosis of malignant pleural mesothelioma by axillary lymph node biopsy. Chest 1987;91:278–81.
Sussman J, Rosai J. Lymph node metastasis as the initial manifestation of malignant mesothelioma: report of six cases. Am J Surg Pathol 1990;14:819–828.
Lloreta J, Serrano S. Pleural mesothelioma presenting as an axillary lymph node metastasis with anemone cell appearance. Ultrastruct Pathol 1994;18:293–298.
Wills EJ. Pleural mesothelioma with initial presentation as cervical lymphadenopathy. Ultrastruct Pathol 1995;19:389–394.
Colby TV. Benign mesothelial cells in lymph node. Adv Anat Pathol 1999;6:41–48.
Sion-Vardy N, Diomin V, Benharroch D. Hyperplastic mesothelial cells in subpleural lymph nodes mimicking metastatic carcinoma. Ann Diagn Pathol 2004;8:373–374.
Walker AN, Mills SE. Surgical pathology of the tunica vaginalis testis and embryologically related mesothelium. Pathol Annu 1988;23;2:125–152.
Nogales FF, Isaac MA, Hardisson D, et al. Adenomatoid tumors of the uterus: an analysis of 60 cases. Int J Gynecol Pathol 2002;21:34–40.
Ordó ñez NG. Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol 2006;13:83–88.
Kaplan MA, Tazelaar HD, Hayashi T, et al. Adenomatoid tumors of the pleura. Am J Surg Pathol 1996;20:1219–1223.
Handra-Luca A, Couvelard A, Abd Alsamad I, et al. Adenomatoid tumor of the pleura. Ann Pathol 2000;20:369–372.
Kannerstein M, Churg J, McCaughey WTE, Hill DP. Papillary tumors of the peritoneum in women: Mesothelioma or papillary carcinoma. Am J Obstet Gynecol 1977;127:306–314.
Goepel JR. Benign papillary mesothelioma of peritoneum: a histological, histochemical and ultrastructural study of six cases. Histopathology 1981;5:21–30.
Burrig KF, Pfitzer P, Hort W. Well-differentiated papillary mesothelioma of the peritoneum: a borderline mesothelioma: report of two cases and review of literature. Virchows Arch A Pathol Anat Histopathol 1990;417:443–447.
Daya D, McCaughey WT. Well-differentiated papillary mesothelioma of the peritoneum: a clinicopathologic study of 22 cases. Cancer 1990;65:292–296.
Lovell FA, Cranston PE. Well-differentiated papillary mesothelioma of the peritoneum. AJR Am J Roentgenol 1990;155:1245–1246.
Daya D, McCaughey WT. Pathology of the peritoneum: a review of selected topics. Semin Diagn Pathol 1991;8:277–289.
Lammer F, Scherrer C, Hacki WH. Well-differentiated papillary mesothelioma of the peritoneum: rare, but prognostically important differential diagnosis. Schweiz Med Wochenschr 1991;121:954–956.
Bouvier S, Baron O, Nomballais F, et al. Well-differentiated papillary mesothelioma of the peritoneum: an attenuated malignant tumor-review of the literature apropos of a case. Bull Cancer 1994;81:104–107.
Mangal R, Taskin O, Franklin R. An incidental diagnosis of well-differentiated papillary mesothelioma in a woman operated on for recurrent endometriosis. Fertil Steril 1995;63:196–197.
Hoekman K, Tognon G, Risse EK, et al. Well-differentiated papillary mesothelioma of the peritoneum: a separate entity. Eur J Cancer 1996;32A:255–258.
Shukunami K, Hirabuki S, Kaneshima M, et al. Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: successful treatment by local and systemic administration of carboplatin. Tumori 2000;86:419–421.
Butnor KJ, Sporn TA, Hammar SP, Roggli VL. Well-differentiated papillary mesothelioma. Am J Surg Pathol 2001;25:1304–1309.
Chetty R. Well differentiated (benign) papillary mesothelioma of the tunica vaginalis. J Clin Pathol 1992;45:1029–1030.
Sane AC, Roggli VL. Curative resection of a well-differentiated papillary mesothelioma of the pericardium. Arch Pathol Lab Med 1995;119:266–267.
Galateau-Sallé F, Vignaud JM, Burke L, et al. Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases. Am J Surg Pathol 2004;28:534–540.
Bolen JW, Hammar SP, McNutt MA. Serosal tissue: reactive tissue as a model for understanding mesotheliomas. Ultrastruct Pathol 1987;11:251–262.
Mayall FG, Gibbs AR. The histology and immunohistochemistry of small cell mesothelioma. Histopathology 1992;20:47–51.
Falconieri G, Zanconati F, Bussani R, Di Bonito L. Small cell carcinoma of lung simulating pleural mesothelioma: report of 4 cases with autopsy confirmation. Pathol Res Prac 1995;191:1147–1152.
Krismann M, Müller K-M, Jaworska M, Johnen G. Pathological anatomy and molecular pathology [of mesothelioma]. Lung Cancer 2004;45S:S29–S33.
Nascimento AG, Keeney GL, Fletcher CDM. Deciduoid peritoneal mesothelioma: an unusual phenotype affecting young females. Am J Surg Pathol 1994;18:439–445.
Gloeckner-Hofmann K, Zhu XZ, Bartels H, et al. Deciduoid pleural mesothelioma affecting a young female without prior asbestos exposure. Respiration 2000;67:456–458.
Okonkwo A, Musunuri S, Diaz L Jr, et al. Deciduoid mesothelioma: a rare, distinct entity with unusual features. Ann Diagn Pathol 2001;5:168–171.
Reis-Filho JS, Pope LZ, Milanezi F, et al. Primary epithelial malignant mesothelioma of the pericardium with deciduoid features: cytohistologic and immunohistochemical study. Diagn Cytopathol 2002;26:117–122.
Serio G, Scattone A, Pennella A, et al. Malignant deciduoid mesothelioma of the pleura: report of two cases with long survival. Histopathology 2002;40:348–352.
Gillespie FR, van der Walt JD, Derias N, Kenney A. Deciduoid peritoneal mesothelioma: a report of the cytological appearances. Cytopathology 2001;12:57–61.
Ordóñez NG. Epithelial mesothelioma with deciduoid features: report of four cases. Am J Surg Pathol 2000;24:816–823.
Puttagunta L, Vriend RA, Nguyen GK. Deciduoid epithelial mesothelioma of the pleura with focal rhab doid change [letter]. Am J Surg Pathol 2000;24:1440–1443.
Shanks JH, Harris M, Banerjee SS, et al. Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am J Surg Pathol 2000;24:285–294.
Talerman A. Deciduoid or pseudodecidual mesothelioma [letter; comment]. Am J Surg Pathol 2000;24:1179.
Monaghan H, Al-Nafussi A. Deciduoid pleural mesothelioma. Histopathology 2001;39:104–106.
Guinee DG, Travis WD. Pitfalls in the diagnosis of malignant mesothelioma. In: Pass HI, Vogelzang NJ, Carbone M, eds. Malignant mesothelioma: advances in pathogenesis, diagnosis, and translational therapies. New York: Springer, 2005:555–578.
Ernst CS, Atkinson BF. Mucicarmine positivity in ma lignant mesothelioma. Lab Invest 1980;42:113–114.
McCaughey WTE, Colby TV, Battifora H, et al. Diag nosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel. Mod Pathol 1991;4:342–353.
Benjamin CJ, Ritchie AC. Histological staining for the diagnosis of mesothelioma. Am J Med Technol 1982;48:905–908.
Mennemeyer R, Smith M. Multicystic, peritoneal mesothelioma: a report with electron microscopy of a case mimicking intra-abdominal cystic hygroma (lymphangioma). Cancer 1979;44:692–698.
Moore JH Jr, Crum CP, Chandler JG, Feldman PS. Benign cystic mesothelioma. Cancer 1980;45:2395–2399.
Blumberg NA, Murray JF. Multicystic peritoneal mesothelioma: a case report. S Afr Med J 1981;59:85–86.
Katsube Y, Mukai K, Silverberg SG. Cystic mesothelioma of the peritoneum: a report of five cases and review of the literature. Cancer 1982;50:1615–1622.
Schneider V, Partridge JR, Gutierrez F, et al. Benign cystic mesothelioma involving the female genital tract: report of four cases. Am J Obstet Gynecol 1983;145:355–359.
Nirodi NS, Lowry DS, Wallace RJ. Cystic mesothelioma of the pelvic peritoneum: two case reports. Br J Obstet Gynaecol 1984;91:201–204.
Philip G, Reilly AL. Benign cystic mesothelioma: case reports. Br J Obstet Gynaecol 1984;91:932–938.
Sienkowski K, Russell AJ, Dilly SA, Djazaeri B. Peritoneal cystic mesothelioma: an electron microscopic and immunohistochemical study of two male patients. J Clin Pathol 1986;39:440–445.
Weiss SW, Tavassoli FA. Multicystic mesothelioma: an analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 1988;12:737–746.
Santucci M, Biancalani M, Dini S. Multicystic peritoneal mesothelioma: a fine structure study with special reference to the spectrum of phenotypic differentiation exhibited by mesothelial cells. J Submicrosc Cytol Pathol 1989;21:749–764.
Pollack CV Jr, Jorden RC. Benign cystic mesothelioma presenting as acute abdominal pain in a young woman. J Emerg Med 1991;9:21–25.
Scucchi L, Mingazzini P, Di Stefano D, et al. Two cases of “multicystic peritoneal mesothelioma”: description and critical review of the literature. Anticancer Res 1994;14:715–720.
Ozgen A, Akata D, Akhan O, et al. Giant benign cystic peritoneal mesothelioma: US, CT, and MRI findings. Abdominal Imaging 1998;23:502–504.
De Toma G, Nicolanti V, Plocco M, et al. Cystic peritoneal mesothelioma: report of a case. Surg Today 2000;30:98–100.
Moghe GM, Krishnamurthy SC. Multicystic mesothelioma of the peritoneum. Indian J Gastroenterol 2001;20:202–203.
Omeroglu A, Husain A. Multilocular peritoneal inclusion cyst (benign cystic mesothelioma). Arch Pathol Lab Med 2001;125:1123–1124.
Petrou G, Macindoe R, Deane S. Benign cystic mesothelioma in a 60-year-old woman after cholecystectomy. ANZ J Surg 2001;71:615–618.
Bui-Mansfield LT, Kim-Ahn G, O’Bryant LK. Multicystic mesothelioma of the peritoneum. AJR 2002;178:402.
Ricci F, Borzellino G, Ghimenton C, Cordiano C. Benign cystic mesothelioma in a male patient: surgical treatment by the laparoscopic route. Surg Laparosc Endosc 1995;5:157–160.
Kumar D, Dhar A, Jain R, et al. Benign cystic peritoneal mesothelioma in a man. Indian J Gastroenterol 1998;17:156–157.
Colombat M, Carton S, Drouard F. Cystic mesothelioma of the peritoneum in a male. Ann Pathol 2000;20:59–61.
Ignjatovic M, Cerovic S, Cuk V. Mesothelial cyst and cystic mesothelioma of the greater omentum: case report and literature review. Acta Chir Iugosl 2001;48:77–83.
Hafner M, Novacek G, Herbst F, et al. Giant benign cystic mesothelioma: a case report and review of literature. Eur J Gastroenterol Hepatol 2002;14:77–80.
Vara-Thorbeck C, Toscano-Mendez R. Peritoneal cystic mesothelioma. Surg Endosc 2002;16:220.
Ross MJ, Welch WR, Scully RE. Multilocular peritoneal inclusion cysts (so-called cystic mesothelioma). Cancer 1989;64:1336–1346.
Groisman GM, Kerner H. Multicystic mesothelioma with endometriosis. Acta Obstet Gynecol Scand 1992;71:642–644.
Drut R, Quijano G. Multilocular mesothelial inclusion cysts (so-called benign multicystic mesothelioma) of pericardium [letter]. Histopathology 1999;34:472–474.
Hutchinson R, Sokhi GS. Multicystic peritoneal mesothelioma: not a benign condition. Eur J Surg 1992;158:451–453.
Miles JM, Hart WR, McMahon JT. Cystic mesothelioma of the peritoneum: report of a case with multiple recurrences and review of the literature. Cleve Clin Q 1986;53:109–114.
Letterie GS, Yon JL. The antiestrogen tamoxifen in the treatment of recurrent benign cystic mesothelioma. Gynecol Oncol 1998;70:131–133.
Gonzalez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH. Malignant transformation of “benign” cystic mesothelioma of the peritoneum. J Surg Oncol 2002;79:243–251.
Ball NJ, Urbanski SJ, Green FH, Kieser T. Pleural multicystic mesothelial proliferation: the so-called multicystic mesothelioma. Am J Surg Pathol 1990;14:375–378.
Henderson DW, Shilkin KB, Whitaker D, et al. Unusual histological types and anatomic sites of mesothelioma. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992:140–166.
Kannerstein M, Churg J. Desmoplastic diffuse malignant mesothelioma. In: Fenoglio CM, Wolff M, eds. Progress in surgical pathology. New York: Masson, 1980:19–29.
Cantin R, Al-Jabi M, McCaughey WT. Desmoplastic diffuse mesothelioma. Am J Surg Pathol 1982;6:215–222.
Du Bray ES, Rosson FB. Primary mesothelioma of the pleura: a clinical and pathologic contribution to pleural malignancy, with report of a case. Arch Intern Med 1920;26:715–737.
Mangano WE, Cagle PT, Churg A, et al. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol 1998;110:191–199.
Wilson GE, Hasleton PS, Chatterjee AK. Desmoplastic malignant mesothelioma: a review of 17 cases. J Clin Pathol 1992;45:295–298.
Churg A. Neoplastic asbestos-induced disease. In: Churg A, Green FHY, eds. Pathology of occupational lung disease, 2nd ed. Baltimore: Williams & Wilkins, 1998:339–391.
Battifora H, McCaughey WTE. Tumors of the serosal membranes. Atlas of tumor pathology, 3rd series, fascicle 15. Washington, DC: Armed Forces Institute of Pathology, 1995.
Machin T, Mashiyama ET, Henderson JAM, McCaughey WTE. Bony metastases in desmoplastic pleural mesothelioma. Thorax 1988;43:155–156.
Henderson DW, Attwood HD, Constance TJ, et al. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol 1988;12:367–384.
Khalidi HS, Medeiros LJ, Battifora H. Lymphohistiocytoid mesothelioma: an often misdiagnosed variant of sarcomatoid mesothelioma. Am J Clin Pathol 2000;113:649–654.
Yao DX, Shia J, Erlandson RA, Klimstra DS. Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review. Ultrastruct Pathol 2004;28:213–228.
Dorfmüller P, Krismann M, Müller K-M. Mesotheliomas with leukocytic infiltration: aspects of differential diagnosis. Pathologe 2004;25:349–355
Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma—possible immunological mechanism. Lung Cancer 2001;32:197–201.
Attanoos RL, Galateau-Salle F, Gibbs AR, et al. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma. Histopathology 2002;41:42–49.
Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982;61:1007–1009.
Crotty TB, Myers JL, Katzenstein AL, et al. Localized malignant mesothelioma: a clinicopathologic and flow cytometric study. Am J Surg Pathol 1994;18:357–363.
Allen TC, Cagle PT, Churg AM, et al. Localized malignant mesothelioma. Am J Surg Pathol 2005;29:866–873.
Myers J, Tazelaar H, Katzenstein AL, et al. Localized malignant epithelioid and biphasic mesothelioma of the pleura: clinicopathologic, immunohistochemical, and flow cytometric analysis of 3 cases. Lab Invest 1992;66:115A.
Ojeda HF, Mech K Jr, Hicken WJ. Localized malignant mesothelioma: a case report. Am Surg 1998;64:881–885.
Churg AM. Localized pleural tumors. In: Cagle PT, ed. Diagnostic pulmonary pathology. New York: Marcel Dekker, 2000:719–735.
Okamura H, Kamei T, Mitsuno A, et al. Localized malignant mesothelioma of the pleura. Pathol Int 2001;51:654–660.
Umezu H, Kuwata K, Ebe Y, et al. Microcystic variant of localized malignant mesothelioma accompanying an adenomatoid tumor-like lesion. Pathol Int 2002;52:416–422.
Zimmerman RL. Effusion cytology: keeping researchers and journals in business for the past 20 years-and it is not over yet. Current Diagn Pathol 2005;11:194–202.
Turbat-Herrera EA, Herrera GA. Electron microscopy renders the diagnostic capabilities of cytopathology more precise: an approach to everyday practice. Ultrastruct Pathol 2005;29:475–482.
Joseph MG, Banerjee D, Harris P, et al. Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry. Mod Pathol 1995;8:686–693.
Ross B, Motherby H, Saurenbach F, et al. Atomic force microscopy in effusion cytology. Anal Quant Cytol Histol 1998;20:97–104.
Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000;11:139–151.
Whitaker D, Sterrett G, Shilkin KB. Mesotheliomas. In: Gray W, ed. Diagnostic cytopathology. Edinburgh: Churchill Livingstone, 1995:195–224.
DeMay RM. Cytology of malignant mesothelioma. In: Pass H, Vogelzang NJ, Carbone M, eds. Malignant mesothelioma. New York: Springer, 2005:481–489.
DeMay RM. The art and science of cytopathology. Chicago: ASCP Press, 1996.
Geisinger KR, Stanley MW, Raab SS, et al. Modern cytopathology. Philadelphia: Churchill Livingstone, 2003.
Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol 2006;13:174–184.
Renshaw AA, Dean BR, Antman KH, et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997;111:106–109.
DiBonito L, Falconieri G, Colautti I, et al. Cytopathology of malignant mesothelioma: a study of its patterns and histological bases. Diagn Cytopathol 1993;9:25–31.
Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003;58(suppl 2):8–17.
Tarn AC, Lapworth R. BTS guidelines for investigation of unilateral pleural effusion in adults. Thorax 2004;59:358–9;author reply 359.
Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J 2001;18:402–419.
Atagi S, Ogawara M, Kawahara M, et al. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn J Clin Oncol 1997;27:293–297.
Boersma A, Degand P, Biserte G. Hyaluronic acid analysis and the diagnosis of pleural mesothelioma. Bull Eur Physiopathol Respir 1980;16:41–45.
Matzel W, Schubert G. Hyaluronic acid in pleural fluids: an additional parameter for clinical diagnosis on diffuse mesotheliomas [German]. Arch Geschwulstforsch 1979;49:146–154.
Welker L, Muller M, Holz O, et al. Cytological diagnosis of malignant mesothelioma-improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 2007;450:455–461.
Creaney J, Yeoman D, Naumoff L, et al. Soluble mesothelin in effusions—a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569–576.
Romero S, Fernandez C, Arriero JM, et al. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996;9:17–23.
Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2002;26:61–66.
Ylagan LR, Zhai J. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Diagn Cytopathol 2005;32:137–144.
Gong Y, Sun X, Michael CW, et al. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs. cell block. Diagn Cytopathol 2003;28:1–5.
Manosca F, Schinstine M, Fetsch PA, et al. Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol 2007;35:6–11.
Whitaker D. Cell aggregates in malignant mesothelioma. Acta Cytol 1977;21:236–239.
Johnson JS, Edwards JM. Malignant mesothelioma mimicking squamous carcinoma in a pleural fluid aspirate. Cytopathology 2001;12:54–56.
Gupta K, Dey P. Cell cannibalism: diagnostic marker of malignancy. Diagn Cytopathol 2003;28:86–87.
Tickman RJ, Cohen C, Varma VA. Distinction between carcinoma cells and mesothelial cells in serous effusions: usefulness of immunohistochemistry. Acta Cytol 1990;34:491–496.
Isobe H, Sridhar KS, Doria R, et al. Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma. Cytometry 1995:86–91.
Motherby H, Pomjanski N, Kube M, et al. Diagnostic DNA-flow-vs.-image-cytometry in effusion cytology. Anal Cell Pathol 2002;24(1):5–15.
Osterheld MC, Liette C, Anca M. Image cytometry: an aid for cytological diagnosis of pleural effusions. Diagn Cytopathol 2005;32:173–176.
Dejmek A, Stromberg C, Wikstrom B, Hjerpe A. Prognostic importance of the DNA ploidy pattern in malignant mesothelioma of the pleura. Anal Quant Cytol Histol 1992;14:217–221.
Jagirdar J, Levine Z, Gallo L, Lee T. Automated argyrophilic nucleolar organizer region (AgNOR) counts in the differential diagnosis of benign vs malignant mesothelial cells. Lab Invest 1992;66:114A.
Pomjanski N, Motherby H, Buckstegge B, et al. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis. Anal Quant Cytol Histol 2001;23:151–160.
Nagel H, Hemmerlein B, Ruschenburg I, et al. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelial versus metastatic tumors in effusion cytology. Pathol Res Prac 1998;194:759–764.
Su XY, Li GD, Liu HB, Jiang LL. Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion [Chin]. Ai Zheng 2004;23:1185–1189.
Ruitenbeek T, Gouw AS, Poppema S. Immunocytology of body cavity fluids: MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994;118:265–269.
Lauritzen AF. Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions. APMIS 1989;97:761–766.
Ko EC, Jhala NC, Shultz JJ, Chhieng DC. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol 2001;116:709–715.
Nance KV, Silverman JF. Immunocytochemical panel for the identification of malignant cells in serous effusions. Am J Clin Pathol 1991;95:867–874.
Dusenbery D, Grimes MM, Frable WJ. Fine-needle aspiration cytology of localized fibrous tumor of pleura. Diagn Cytopathol 1992;8:444–450.
Sterrett GF, Whitaker D, Shilkin KB, Walters MN. Fine needle aspiration cytology of malignant mesothelioma. Acta Cytol 1987;31:185–193.
Nguyen GK, Akin MR, Villanueva RR, Slatnik J. Cytopathology of malignant mesothelioma of the pleura in fine-needle aspiration biopsy. Diagn Cytopathol 1999;21:253–259.
Silverman JF, Berns LA, Holbrook CT, et al. Fine needle aspiration cytology of primitive neuroectodermal tumors: a report of these cases. Acta Cytol 1992;36:541–550.
Spanta R, Saleh HA, Khatib G. Fine needle aspiration diagnosis of extraadrenal myelolipoma presenting as a pleural mass: a case report. Acta Cytol 1999;43:295–298.
Taylor CA, Barnhart A, Pettenati MJ, Geisinger KR. Primary pleuropulmonary synovial sarcoma diagnosed by fine needle aspiration with cytogenetic confirmation: a case report. Acta Cytol 2005;49:673–676.
Cho EY, Han JJ, Han J, Oh YL. Fine needle aspiration cytology of solitary fibrous tumours of the pleura. Cytopathology 2007;18:20–27.
Yu GH, Soma L, Hahn S, Friedberg JS. Changing clinical course of patients with malignant mesothelioma: implications for FNA cytology and utility of immunocytochemical staining. Diagn Cytopathol 2001;24:322–327.
Tafazzoli A, Raza A, Martin SE. Primary diagnosis of malignant mesothelioma by fine-needle aspiration of a supraclavicular lymph node. Diagn Cytopathol 2005;33:122–125.
Yu GH, Baloch ZW, Gupta PK. Cytomorphology of metastatic mesothelioma in fine-needle aspiration specimens. Diagn Cytopathol 1999;20:328–332.
Cimbaluk D, Kasuganti D, Kluskens L, et al. Malignant biphasic pleural mesothelioma metastatic to the liver diagnosed by fine-needle aspiration. Diagn Cytopathol 2006;34:33–36.
Sneige N, Holder PD, Katz RL, et al. Fine-needle aspiration cytology of the male breast in a cancer center. Diagn Cytopathol 1993;9:691–697.
Schmid KW, Hittmair A, Ofner C, et al. Metastatic tumors in fine needle aspiration biopsy of the thyroid. Acta Cytol 1991;35:722–724.
Adams RF, Gray W, Davies RJ, Gleeson FV. Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest 2001;120:1798–1802.
Vargas FS, Teixeira LR. Pleural malignancies. Curr Opin Pulm Med 1996;2:335–340.
Bonomo L, Feragalli B, Sacco R, et al. Malignant pleural disease. Eur J Radiol 2000;34:98–118.
Matthay RA, Coppage L, Shaw C, Filderman AE. Malignancies metastatic to the pleura. Invest Radiol 1990;25:601–619.
Sahn SA. Malignancy metastatic to the pleura. Clin Chest Med 1998;19:351–361.
Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977;63:695–702.
Pomjanski N, Grote HJ, Doganay P, et al. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol 2005;33:309–315.
Medford A, Maskell N. Pleural effusion. Postgrad Med J 2005;81:702–710.
Hammar SP, Dodson RF. Asbestos. In: Dail DH, Hammar SP, eds. Pulmonary pathology, 2nd ed. New York: Springer-Verlag, 1994:901–983.
Harwood TR, Gracey DR, Yokoo H. Pseudomesotheliomatous carcinoma of the lung: a variant of peripheral lung cancer. Am J Clin Pathol 1976;65:159–167.
Braganza JM, Butler EB, Fox H, et al. Ectopic production of salivary type amylase by a pseudomesotheliomatous carcinoma of the lung. Cancer 1978;41:1522–1525.
Broghamer WL Jr, Collins WM, Mojsejenko IK. The cytohistopathology of a pseudomesotheliomatous carcinoma of the lung. Acta Cytol 1978;22:239–242.
Tanaka I, Inoue M, Futonaka H, et al. An autopsy case of pseudomesotheliomatous lung cancer presenting as pneumothorax [Japanese]. Jap J Thorac Dis 1979;17:582–587.
Lin JI, Tseng CH, Tsung SH. Pseudomesotheliomatous carcinoma of the lung. South Med J 1980;73:655–657.
Nishimoto Y, Ohno T, Saito K. Pseudomesotheliomatous carcinoma of the lung with histochemical and immunohistochemical study. Acta Pathol Jap 1983;33:415–423.
Simonsen J. Pseudomesotheliomatous carcinoma of the lung with asbestos exposure. Am J Forens Med Pathol 1986;7:49–51.
Dessy E, Pietra GG. Pseudomesotheliomatous carcinoma of the lung: an immunohistochemical and ultrastructural study of three cases. Cancer 1991;68:1747–1753.
Koss M, Travis W, Moran C, Hochholzer L. Pseudomesotheliomatous adenocarcinoma: a reappraisal. Semin Diagn Pathol 1992;9:117–123.
Moch H, Kiener S, Dalquen P, Gudat F. Pseudomesotheliomatous adenocarcinoma of the lung: immunohistochemical study with special reference to detection of blood group isoantigens and Ber-EP4 antigen [German]. Pathologe 1993;14:11–15.
Hartmann CA, Schütze H. Mesothelioma-like tumors of the pleura: a review of 72 autopsy cases. J Cancer Res Clin Oncol 1994;120:331–347.
Brunner-La Rocca HP, Schlossberg D, Vogt P. Pseudomesotheliomatous carcinoma in HIV infection [German]. Dtsch Med Wochenschr 1995;120:1312–1317.
Schreiner SR, Kirkpatrick BD, Askin FB. Pseudomesotheliomatous adenocarcinoma of the lung in a patient with HIV infection. Chest 1998;113:839–841.
Oka K, Otani S, Yoshimura T, et al. Mucin-negative pseudomesotheliomatous adenocarcinoma of the lung: report of three cases. Acta Oncol 1999;38:1119–1121.
Yuasa H, Tomoyasu M. Clinical comparison of diffuse malignant mesothelioma of the pleura and pseudomesotheliomatous carcinoma of the lung for each case [Japanese]. Jpn J Thorac Surg 1999;52:836–839.
Attanoos RL, Gibbs AR. “Pseudomesotheliomatous” carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology 2003;43:444–452.
Taylor DR, Page W, Hughes D, Varghese G. Metastatic renal cell carcinoma mimicking pleural mesothelioma. Thorax 1987;42:901–902.
Ohgou T, Okahara M, Kishimoto T. Renal cell carcinoma with many transvenous pleural metastases [Japanese]. Nihon Kokyuki Gakkai Zasshi 1998;36:369–373.
Azuma T, Nishimatsu H, Nakagawa T, et al. Metastatic renal cell carcinoma mimicking pleural mesothelioma. Scand J Urol Nephrol 1999;33:140–141.
Huncharek M, Muscat J. Metastatic laryngeal carcinoma mimicking pleural mesothelioma. Respiration 1991;58:204–206.
Hartmann CA, Minck C. Metastatic cystosarcoma phyllodes with pseudomesotheliomatous sarcomatosis of the contralateral pleura [German]. Pathologe 1988;9:119–123.
Babolini G, Blasi A. The pleural form of primary carcinoma of the lung. Dis Chest 1956;29:314–323.
Bollinger DJ, Wick MR, Dehner LP, al e. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma: a histochemical and immunohistochemical comparison. Am J Surg Pathol 1989;13:659–670.
Raju U, Fine G, Greenawald KA, Ohorodnik JM. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases. Hum Pathol 1989;20:426–436.
Wick MR, Mills SE, Dehner LP, et al. Serous papillary carcinomas arising from the peritoneum and ovaries: a clinicopathologic and immunohistochemical comparison. Int J Gynecol Pathol 1989;8:179–188.
Truong LD, Maccato ML, Awalt H, et al. Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol 1990;21:99–110.
Khoury N, Raju U, Crissman JD, et al. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. Hum Pathol 1990;21:811–819.
Meis-Kindblom JM, Kindblom LG, Enzinger FM. Sclerosing epithelioid fibrosarcoma: a variant of fibrosarcoma simulating carcinoma. Am J Surg Pathol 1995;19:979–993.
Antonescu CR, Rosenblum MK, Pereira P, et al. Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol 2001;25:699–709.
Rosai J, Gorich J. Pleural metastasis of malignant thymoma: a pitfall in the CT-diagnosis of pleural mesothelioma. Am J Surg Pathol 1990;14:819–828.
Payne CB, Jr,, Morningstar WA, Chester EH. Thymoma of the pleura masquerading as diffuse mesothelioma. Am Rev Respir Dis 1966;94:441–446.
Honma K, Shimada K. Metastasizing ectopic thymoma arising in the right thoracic cavity and mimicking diffuse pleural mesothelioma: an autopsy study of a case with review of the literature. Wien Klin Wochenschr 1986;98:14–20.
Moran CA, Travis WD, Rosada-de-Christenson M, et al. Thymomas presenting as pleural tumors: report of eight cases. Am J Surg Pathol 1992;16:138–144.
Fushimi H, Tanio Y, Kotoh K. Ectopic thymoma mimicking diffuse pleural mesothelioma: a case report. Hum Pathol 1998;29:409–410.
Attanoos RL, Gibbs AR. Unusual “pseudomesotheliomatous” neoplasms: primary pleural thymic epithelial tumours. Histopathology 2002;41(suppl 2):170–173.
Travis WD, Brambilla E, Müller-Hermelink HK, Harris C, eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC, 2004:128–136.
Corson JM, Weiss LM, Banks-Schlegel SP, Pinkus G. Keratin proteins and carcinoembryonic antigen in synovial sarcomas: an immunohistochemical study of 24 cases. Hum Pathol 1984;15:615–621.
Nakamura T, Nakata K, Hata S, et al. Histochemical characterization of mucosubstances in synovial sarcoma. Am J Surg Pathol 1984;8:429–434.
Abenoza P, Manivel JC, Swanson PE, Wick MR. Synovial sarcoma: ultrastructural study and immunohistochemical analysis by a combined peroxidase-antiperoxidase/avidin-biotin-peroxidase complex procedure. Hum Pathol 1986;17:1107–1115.
Fisher C. Synovial sarcoma: ultrastructural and immunohistochemical features of epithelial differentiation in monophasic and biphasic tumors. Hum Pathol 1986;17:996–1008.
Ordóñez NG, Mahfouz SM, Mackay B. Synovial sarcoma: an immunohistochemical and ultrastructural study. Hum Pathol 1990;21:733–749.
Dickersin GR. Synovial sarcoma: a review and update, with emphasis on the ultrastructural characterization of the nonglandular component. Ultrastruct Pathol 1991;15:379–402.
Fisher C. Synovial sarcoma. Ann Diagn Pathol 1998;2:401–421.
Powers A, Carbone M. Diagnosis of synovial sarcoma of the pleura and differentiation from malignant mesothelioma. In: Pass HI, Vogelzang NJ, Carbone M, eds. Malignant mesothelioma: advances in pathogenesis, diagnosis, and translational therapies. New York: Springer, 2005:543–554.
Witkin GB, Miettinen M, Rosai J. A biphasic tumor of the mediastinum with features of synovial sarcoma. A report of four cases. Am J Surg Pathol 1989;13:490–499.
Suster S, Moran CA. Primary synovial sarcomas of the mediastinum: a clinicopathologic, immunohistochemical and ultrastructural study of 15 cases. Am J Surg Pathol 2005;29:569–578.
Nicholson AG, Rigby M, Lincoln C, et al. Synovial sarcoma of the heart. Histopathology 1997;30:349–352.
Langner K, Schafer R, Muller KM, Goller T. Synovial sarcoma of the pericardium [German]. Pathologe 1998;19:442–446.
Al-Rajhi N, Husain S, Coupland R, et al. Primary pericardial synovial sarcoma: a case report and literature review. J Surg Oncol 1999;70:194–198.
Vander Salm TJ. Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg 2000;12:89–100.
Hisaoka M, Hashimoto H, Iwamasa T, et al. Primary synovial sarcoma of the lung: report of two cases confirmed by molecular detection of SYT-SSX fusion gene transcripts. Histopathology 1999;34:205–210.
Keel SB, Bacha E, Mark EJ, et al. Primary pulmonary sarcoma: a clinicopathologic study of 26 cases. Mod Pathol 1999;12:1124–1131.
Aubry MC, Bridge JA, Wickert R, Tazelaar HD. Primary monophasic synovial sarcoma of the pleura: five cases confirmed by the presence of the SYT-SSX fusion transcript. Am J Surg Pathol 2001;25:776–781.
Colwell AS, D’Cunha J, Vargas SO, et al. Synovial sarcoma of the pleura: a clinical and pathologic study of three cases. J Thorac Cardiovasc Surg 2002;124:828–832.
Essary LR, Vargas SO, Fletcher CD. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset. Cancer 2002;94:459–469.
Hirano H, Kizaki T, Sashikata T, et al. Synovial sarcoma arising from the pleura: a case report with ultrastructural and immunohistochemical studies. Med Electron Microsc 2002;35:102–108.
Chan JA, McMenamin ME, Fletcher CDM. Synovial sarcoma in older patients: clinicopathologic analysis of 32 cases with emphasis on unusual histological features. Histopathology 2003;43:72–83.
Ng SB, Ahmed Q, Tien SL, et al. Primary pleural synovial sarcoma: a case report and review of the literature. Arch Pathol Lab Med 2003;127:85–90.
Vohra HA, Davies S, Vohra H, et al. Primary synovial sarcoma of the pleura: beware of misdiagnosis. Eur J Intern Med 2004;15:465–466.
Ghadially FN. Fine structure of synovial joints: a text and atlas of the ultrastructure of normal and pathological articular tissues. London: Butterworths, 1983.
Ghadially FN. Diagnostic electron microscopy of tumours, 2nd ed. London: Butterworths, 1985.
Henderson DW, Papadimitriou JM, Coleman M. Ultrastructural appearances of tumours. Diagnosis and classification of human neoplasia by electron microscopy, 2nd ed. Edinburgh: Churchill Livingstone, 1986.
Erlandson RA. Diagnostic transmission electron microscopy of tumors, with clinicopathological, immunohistochemical, and cytogenetic correlations. New York: Raven Press, 1994.
Kashima T, Matsushita H, Kuroda M, et al. Biphasic synovial sarcoma of the peritoneal cavity with t(X;18) demonstrated by reverse transcriptase polymerase chain reaction. Pathol Int 1997;47:637–641.
Praet M, Forsyth R, Dhaene K, et al. Synovial sarcoma of the pleura: report of four cases. Histopathology 2002;41:147–149.
Maruyama R, Mitsudomi T, Ishida T, et al. Aggressive pulmonary metastasectomies for synovial sarcoma. Respiration 1997;64:316–318.
England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura: a clinicopathologic review of 223 cases. Am J Surg Pathol 1989;13:640–658.
Briselli M, Mark EJ, Dickersin GR. Solitary fibrous tumors of the pleura: eight new cases and review of 360 cases in the literature. Cancer 1981;47:2678–2689.
Moran CA, Suster S, Koss MN. The spectrum of histologic growth patterns in benign and malignant fibrous tumors of the pleura. Semin Diagn Pathol 1992;9:169–180.
Van de Rijn M, Lombard CM, Rouse RV. Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung. Am J Surg Pathol 1994;18:814–820.
Segawa D, Yoshizu H, Haga Y, et al. Successful operation for solitary fibrous tumor of the epicardium. J Thorac Cardiovasc Surg 1995;109:1246–1248.
Kawashima K, Yokoi K, Matsuguma H, et al. Huge localized mesothelioma of the diaphragm in a 17-year-old female—a case report with calculated tumor volume doubling time. Nippon Kyobu Geka Gakkai Zasshi 1998;46:225–230.
Chang YL, Lee YC, Wu CT. Thoracic solitary fibrous tumor: clinical and pathological diversity. Lung Cancer 1999;23:53–60.
Mentzel T, Bainbridge TC, Katenkamp D. Solitary fibrous tumour: clinicopathological, immunohistochemical, and ultrastructural analysis of 12 cases arising in soft tissues, nasal cavity and nasopharynx, urinary bladder and prostate. Virchows Arch 1997;430:445–453.
Fukunaga M, Naganuma H, Nikaido T, et al. Extrapleural solitary fibrous tumor: a report of seven cases. Mod Pathol 1997;10:443–450.
Segers K, Rodeck U, Backhovens H, et al. Solitary fibrous tumour of the orbit. J Pathol 1997;181:67–74.
Ing EB, Kennerdell JS, Olson PR, et al. Solitary fibrous tumor of the orbit. Ophthalmol Plast Reconstr Surg 1998;14:57–61.
Zamecnik M, Michal M. Solitary fibrous tumor (fibrous mesothelioma): report of 2 cases in an extraserous location. Cesk Patol 1998;34:58–62.
Festa S, Lee HJ, Langer P, Klein KM. Solitary fibrous tumor of the orbit: CT and pathologic correlation. Neuroradiology 1999;41:52–54.
Alobid I, Alos L, Blanch JL, et al. Solitary fibrous tumour of the nasal cavity and paranasal sinuses. Acta Otolaryngol 2003;123:71–74.
Ferrario F, Piantanida R, Spriano G, et al. Solitary fibrous tumor of the nasopharynx: apropos of a case. Ann Oto-Laryngol Chirurg Cervico-Faciale 1997;114:71–75.
Abe S, Imamura T, Tateishi A, et al. Intramuscular solitary fibrous tumor: a clinicopathological case study. J Comput Assist Tomogr 1999;23:458–462.
Piazza R, Blandamura S, Zattoni F, et al. Solitary fibrous tumour of the retroperitoneum mimicking a renal mass. Int Urol Nephrol 1996;28:751–754.
Leite KRM, Srougi M, Miotto A, Camara-Lopes LH. Solitary fibrous tumor in the bladder wall. Int Braz J Urol 2004;30:406–409.
Vadmal MS, Pellegrini AE. Solitary fibrous tumor of the vagina. Am J Dermatopathol 2000;22:83–86.
Thompson M, Cheng LHH, Stewart J, et al. A pediatric case of a solitary fibrous tumor of the parotid gland. Int J Pediatric Otorhinolaryngol 2004;68:481–487.
Kie JH, Kim JY, Park YN, et al. Solitary fibrous tumour of the thyroid. Histopathology 1997;30:365–368.
Levine TS, Rose DS. Solitary fibrous tumour of the liver. Histopathology 1997;30:396–397.
Hardisson D, Limeres MA, Jimenez-Heffernan JA, et al. Solitary fibrous tumor of the mesentery. Am J Gastroenterol 1996;91:810–811.
Cardillo G, Facciolo F, Cabazzana AO, et al. Localized (solitary) fibrous tumors of the pleura: an analysis of 55 patients. Ann Thorac Surg 2000;70:1808–812.
Kanamori Y, Hashizume K, Sugiyama M, et al. Intrapulmonary solitary fibrous tumor in an eight-year-old male. Pediatr Pulmonol 2005;40:262–264.
Henderson DW, Klebe S. Tumors, benign. In: Laurent GJ, Shapiro SD, eds. Encyclopedia of respiratory medicine, vol. 4. Oxford: Elsevier, 2006:312.
Mori K, Ohtsuki Y, Hizuka N. Solitary fibrous tumor of the pleura with elevated high-molecular-weight insulin-like growth factor II and hypoglycemia. Nihon Kokyuki Gakkai Zasshi 1999;37:834–840.
Gold JS, Antonescu CR, Hajdu C, et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer 2002;94:1057–1068.
Chilosi M, Facchettti F, Dei Tos AP, et al. Bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol 1997;181:362–367.
Renshaw AA. O13 (CD99) in spindle cell tumors: reactivity with hemangiopericytoma, solitary fibrous tumors, synovial sarcoma, and meningioma, but rarely with sarcomatoid mesothelioma. Appl Immunohistochem 1995;3:250–256.
De Saint Aubain Somerhausen N, Rubin BP, Fletcher CD. Myxoid solitary fibrous tumor: a study of seven cases with emphasis on differential diagnosis. Mod Pathol 1999;12:463–471.
Yokoi T, Tsuzuki M, Yatabe Y, et al. Solitary fibrous tumor: significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology 1998;32:423–432.
Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with reference to CD117 (KIT). Mod Pathol 2000;13:1134–1142.
Butnor KJ, Burchette JL, Sporn TA, et al. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004;128:538–543.
Kayser K, Trott J, Bohm G, et al. Localized fibrous tumors (LFT’s) of the pleura: clinical data, asbestos burden, and syntactic structure analysis applied to newly defined angiogenic/growth-regulatory effectors. Pathol Res Pract 2005;201:791–801.
Vallat-Decouvelaere AV, Dry SM, Fletcher CD. Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability in intrathoracic tumors. Am J Surg Pathol 1998;22:1501–1511.
Erasmus JJ, McAdams HP, Patz EFJ, et al. Calcifying fibrous pseudotumor of the pleura: radiologic features in three cases. J Comput Assist Tomogr 1996;20:63–65.
Pinkard NB, Wilson RW, Lawless N, et al. Calcifying fibrous pseudotumor of pleura: a report of three cases of a newly described entity involving the pleura. Am J Clin Pathol 1996;105:189–194.
Nascimento AE, Ruiz R, Hornick JL, Fletcher CD. Calcifying fibrous “pseudotumor”: clinicopathologic study of 15 cases and analysis of its relationship to inflammatory myofibroblastic tumor. Int J Surg Pathol 2002;10:189–196.
Hainaut P, Lesage V, Weynand B, et al. Calcifying fibrous pseudotumor (CFPT): a patient presenting with multiple pleural lesions. Acta Clin Belg 1999;54:162–164.
Reed MK, Margraf LR, Nikaidoh H, Cleveland DC. Calcifying fibrous pseudotumor of the chest wall. Ann Thorac Surg 1996;62:873–874.
Dumont P, de Muret A, Skrobala D, et al. Calcifying fibrous pseudotumor of the mediastinum. Ann Thorac Surg 1997;63:543–544.
Jeong HS, Lee GK, Sung R, et al. Calcifying fibrous pseudotumor of mediastinum: a case report. J Korean Med Sci 1997;12:58–62.
Kocova L, Michal M, Sulc M, et al. Calcifying fibrous pseudotumor of visceral peritoneum. Histopathology 1997;31:182–184.
Ben-Izhak O, Czernobilsky B. Calcifying fibrous pseudotumor of the mesentery presenting with acute peritonitis: case report with immunohistochemical study and review of the literature. Int J Surg Pathol 2001;9:249–253.
Van Dorpe J, Ectors N, Geboes K, et al. Is calcifying fibrous pseudotumor a late sclerosing stage of inflammatory myofibroblastic tumor? Am J Surg Pathol 1999;23:329–335.
Hill KA, Gonzalez-Crussi F, Chou PM. Calcifying fibrous pseudotumor versus inflammatory myofibroblastic tumor: a histological and immunohistochemical comparison. Mod Pathol 2001;14:784–790.
Sigel JF, Smith TA, Reith JD, Goldblum JR. Immunohistochemical analysis of anaplastic lymphoma kinase expression in deep soft tissue calcifying fibrous pseudotumor: evidence of a late sclerotic phase of inflammatory myofibroblastic tumor? Ann Diagn Pathol 2001;5:10–14.
Maeda A, Kawabata K, Kusuzaki K. Rapid recurrence of calcifying fibrous pseudotumor (a case report). Anticancer Res 2002;22:1795–1797.
Wilson RW, Galateau-Sallé F, Moran CA. Desmoid tumors of the pleura: a clinicopathologic mimic of localized fibrous tumor. Mod Pathol 1999;12:9–14.
Andino L, Cagle PT, Murer B, et al. Pleuropulmonary desmoids tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of β-catenin and cyclin D1 expression. Arch Pathol Lab Med 2006;130:1503–1509.
Fletcher C, Krishman A, Mertens F. Tumor of soft tissue and bone. Lyon: WHO/IARC Press, 2002.
Ordonez NG, Tornos C. Malignant peripheral nerve sheath tumor of the pleura with epithelial and rhabdomyoblastic differentiation: report of a case clinically simulating mesothelioma. Am J Surg Pathol 1997;21:1515–1521.
Galateau-Sallé F, ed. International Mesothelioma Panel: Brambilla E, Cagle PT, Churg AM, et al. Differential diagnosis: non-mesothelial tumors of serosal cavity: sarcomas. In: Pathology of malignant mesothelioma. London: Springer, 2006:169.
Snyder CS, Dell-Aquila N, Munson P, et al. Clonal changes in inflammatory pseudotumor of lung. Cancer 1995;76:1545–1549.
Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for carcinoma. Cancer 1882;50:970–981.
Battifora H. Epithelioid hemangioendothelioma imitating mesothelioma. Appl Immunohistochem 1993;1:220–221.
Lin BT-Y, Colby T, Gown AM, et al. Malignant vascular tumors of the serous membranes mimicking mesothelioma. Am J Surg Pathol 1996;20:1431–1439.
Attanoos RL, Dallimore NS, Gibbs AR. Primary epithelioid haemangioendothelioma of the peritoneum: an unusual mimic of diffuse malignant mesothelioma. Histopathology 1997;30:375–377.
Crotty EJ, McAdams HP, Erasmus JJ, et al. Epithelioid hemangioendothelioma of the pleura: clinical and radiologic features. AJR Am J Roentgenol 2000;175:1545–1549.
Sporn TA, Butnor KJ, Roggli VL. Epithelioid haemangioendothelioma of the pleura: an aggressive vascular malignancy and clinical mimic of malignant mesothelioma. Histopathology 2002;41:173–177.
Al-Shraim M, Mahboub B, Neligan PC, et al. Primary pleural epithelioid haemangioendothelioma with metastases to the skin: a case report and literature review. J Clin Pathol 2005;58:107–109.
Attanoos RL, Suvarna SK, Rhead E, et al. Malignant vascular tumours of the pleura in “asbestos” workers and endothelial differentiation in malignant mesothelioma. Thorax 2000;55:860–863.
Oliveira A, Carvalho L. Epithelioid haemangioendothelioma of the pleura: 29 months survival. Rev Port Pneumol 2006;12:455–461.
Parkash V, Gerald WL, Parma A, et al. Desmoplastic small round cell tumor of the pleura. Am J Surg Pathol 1995;19:659–665.
Sapi Z, Szentirmay Z, Orosz Z. Desmoplastic small round cell tumor of the pleura: a case report with further cytogenetic and ultrastructural evidence of mesothelial “blastemic” origin. Eur J Surg Oncol 1999;25:633–634.
Venkateswaran L, Jenkins JJ, Kaste SC, et al. Disseminated intrathoracic desmoplastic small round-cell tumor: a case report. J Pediatr Hematol Oncol 1997;19:172–175.
Liu J, Nau MM, Yeh JC, et al. Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors. Clin Cancer Res 2000;6:3522–3529.
Dehner LP. Primitive neuroectodermal tumor and Ewing’s sarcoma. Am J Surg Pathol 1993;17:1–13.
Perlman EJ, Dickman PS, Askin FB, et al. Ewing’s sarcoma—routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children Cancer Group Intergroup Study. Hum Pathol 1994;25:304–307.
Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing’s sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 1994;18:486–494.
Manivel JC, Priest JR, Watterson J, et al. Pleuropulmonary blastoma: the so-called pulmonary blastoma of childhood. Cancer 1988;62:1516–1526.
Ansari MQ, Dawson DB, Nador R, et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 1996;105:221–229.
Banks PM, Warnke RA. Primary effusion lymphoma. In: WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:179–180.
Banks PM, Harris NL, Warnke RA. Primary effusion lymphoma. In: Travis WD, Brambilla E, eds. WHO classification of tumors of the lung, pleura and mediastinum. Lyon: IARC Press, 2004.
Aozasa K, Ohsaw AM, Kanno H. Pyothorax-associated lymphoma: a distinctive type of lymphoma strongly associated with Epstein-Barr virus. Adv Anat Pathol 1997;4:58–63.
Gaulard P, Harris NL. Pyothorax-associated lymphoma. In: Travis WD, Brambilla E, eds. WHO classification of tumors of the lung, pleura and mediastinum. Lyon: IARC Press, 2004.
Ibuka T, Fukayama M, Hayashi Y, et al. Pyothorax-associated pleural lymphoma. Cancer 1994;73:738–744.
Uluba G, Eynboglu FO, Simek A, Ozyilkan O. Multiple myeloma with pleural involvement: a case report. Am J Clin Oncol 2005;28:429–430.
Giuliani N, Caramatti C, Roti G, et al. Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. J Clin Oncol 2003;21:1887–1888.
Quinquenel ML, Moualla M, Le Coz A, et al. Pleural involvement of myeloma. Apropos of two cases. Rev Mal Respir 1995;12:173–174.
Vega F, Padula A, Valbuena JR, et al. Lymphomas involving the pleura: a clinicopathologic study of 34 cases diagnosed by pleural biopsy. Arch Pathol Lab Med 2006;130:1497–1502.
Bourantas KL, Tsiara S, Pantel IA, et al. Pleural effusion in chronic myelomonocytic leukemia. Acta Hematol 1998;99:34–37.
Schmitt-Graff A, Wickenhauser C, Kvasnicka HM, et al. Extramedullary initial manifestations of acute myeloid leukemia (AML). Pathologe 2002;23:397–404.
Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612–1616.
Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005;19:1025–1040.
Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein—a blood test for mesothelioma. Lung Cancer 2005;49:S109–S111.
Robinson BWS, Musk A, Lake R. Malignant mesothelioma. Lancet 2005;366:397–408.
Creaney J, Christansen H, Lake R, et al. Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006;1:172–174.
Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor parker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447–453.
Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med ACJRCCM Articles in Press: e-publication 2006; doi:10.1164/rccm.200511-1789OC.
Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK™: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666–672.
Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564–1573.
Cullen M. Serum osteopontin levels—is it time to screen asbestos-exposed workers for pleural mesothelioma? [editorial]. N Engl J Med 2005;353:1617–1618.
Gigerenzer G. Calculated risks: how to know when numbers deceive you. New York: Simon & Schuster, 2002. Published in the United Kingdom as Reckoning with risk: learning to live with uncertainty. London: Allen Lane, 2002.
Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190–9198.
Yen MJ, Hsu C-Y, Mao T-L, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006;12:827–831.
Ho M, Bera TK, Willingham MC, et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007;13:1571–1575.
Baruch AC, Wang H, Staerkel GA, et al. Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol 2007;35:143–147.
Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 2006;56:649–654.
Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC mesothelin in the sera of mesothelioma patients. Cancer Sci 2006;97:928–932.
Huang CY, Cheng WF, Lee CN, et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res 2006;26:4721–4728.
Haylock DN, Nilsson SK. Osteopontin: a bridge between bone and blood. Br J Haematol 2006;134:467–474.
Vordermark D, Said HM, Katzer A, et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006;6:207: doi:10.1186/471-2407-6-207.
Teo M, Kodama S, Nomi N, et al. Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx 2007;34:343–346.
Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 2007;14:373–381.
Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2007;56:782–789.
Kim J, Ki SS, Lee SD, et al. Elevated levels of osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006;101:2051–2059.
Mishima R, Takeshima F, Sawai T, et al. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol 2007;41:167–172.
Friman C, Hellstrom PE, Juvani M, Riska H. Acid glycosaminoglycans (mucopolysaccharides) in the differential diagnosis of pleural effusion. Clin Chim Acta 1977;76:357–361.
Arai H, Kang K, Sato H, et al. Significance of the quantification and demonstration of hyaluronic acid in tissue specimens for the diagnosis of pleural mesothelioma. Am Rev Respir Dis 1979;120:529–532.
Castor CW, Naylor B. Acid mucopolysaccharide composition of serous effusions. Cancer 1967;20:462–466.
Rasmussen KN, Faber V. Hyaluronic acid in 247 pleural fluids. Scand J Respir Dis 1967;48:366–371.
Thompson ME, Bromberg PA, Amenta JS. Acid mucopolysaccharide determination: a useful adjunct for the diagnosis of malignant mesothelioma with effusion. Am J Clin Pathol 1969;52:335–339.
Katayam N, Tokuda A, Nakatsumi Y, et al. A case of malignant mesothelioma presenting with recurrent pneumothorax. Nihon Kokyuki Gakkai Zasshi 2006;44:807–811.
Pettersson T, Froseth B, Rista H, Klockars M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988;94:1037–1039.
Hillerdal G, Lindqvist U, Engstrom-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer 1991;67:2410–2414.
Soderblom T, Pettersson T, Nyberg P, et al. High pleural fluid hyaluronan concentrations in rheumatoid arthritis. Eur Respir J 1999;13:519–522.
Chiu B, Churg A, Tengblad A, Pearce R, McCaughey WTE. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer 1984;54:2195–2199.
Nakano T, Fujii J, Tamura S, et al. Glycosaminoglycan in malignant pleural mesothelioma. Cancer 1986;57:106–110.
Iozzo RV. Biology of disease. Proteoglycans: structure, function and role in neoplasia. Lab Invest 1985;53:373–396.
Iozzo RV, Goldes JA, Chen W-J, Wight JN. Glycosaminoglycans of pleural mesothelioma: a possible biochemical variant containing chondroitin sulfate. Cancer 1981;48:89–97.
Afify AM, Stern R, Michael CW. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol 2005;32:145–150.
Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant mesothelioma. Cancer 2001;92:1224–1230.
Monti G, Jaurand MC, Monnet I, et al. Intrapleural production of interleukin-6 during mesothelioma and its modulation by gamma interferon treatment. Cancer Res 1994;54:4419–4423.
Langlois SL, Henderson DW. Radiological investigation of mesothelioma. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992:259–77.
Nind NR, Attanoos RL, Gibbs AR. Unusual intraparenchymal growth patterns of malignant pleural mesothelioma. Histopathology 2003;42:150–155.
Felner KJ, Wieczorek R, Kline M, et al. Malignant mesothelioma masquerading as a multinodular bronchioloalveolar cell adenocarcinoma with widespread pulmonary nodules. Int J Surg Pathol 2006;14:229–233.
Jones JSP, ed. Pathology of the mesothelium. London: Springer-Verlag, 1987.
Solomons K, Polakow R, Marchand P. Diffuse malignant mesothelioma presenting as bilateral malignant lymphangitis. Thorax 1985;40:682–683.
Musk AW, Dewar J, Shilkin KB, Whitaker D. Miliary spread of malignant pleural mesothelioma without a clinically identifiable pleural tumour. Aust NZ J Med 1991;21:460–462.
Kaye JA, Wang A-M, Joachim CL, et al. Malignant mesothelioma with brain metastases. Am J Med 1986;80:95–97.
Asoh Y, Nakamura M, Maeda T, et al. Brain metastasis from primary pericardial mesothelioma: case report. Neurol Med Chir 1990;30:884–887.
Bohn U, Gonzalez JL, Martin LM, et al. Meningeal and brain metastases in primary malignant pericardial mesothelioma [letter]. Ann Oncol 1994;5:660–661.
Kitai R, Kabuto M, Kawano H, et al. Brain metastasis from malignant mesothelioma—case report. Neurol Med Chir 1995;35:172–174.
Kawai A, Nagasaka Y, Muraki M, et al. Brain metastasis in malignant pleural mesothelioma. Intern Med 1997;36:591–594.
Cheeseman SL, Ranson MR. Cerebral metastases in malignant mesothelioma: a case report. Eur J Cancer Care 1999;8:104–106.
Kobayashi S, Ida M, Matsui O, et al. Lipomatous change in a brain metastasis from malignant pleural mesothelioma. Neuroradiology 2001;43:159–161.
Dutt PL, Baxter JW, O’Malley FP, et al. Distant cutaneous metastasis of pleural malignant mesothelioma. J Cutan Pathol 1992;19:490–495.
Prieto VG, Kenet BJ, Varghese M. Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma. Am J Dermatopathol 1997;19:261–265.
Kubota K, Furuse K, Kawahara M, et al. A case of malignant pleural mesothelioma with metastasis to the orbit. Jpn J Clin Oncol 1996;26:469–471.
Piattelli A, Fioroni M, Rubini C. Tongue metastasis from a malignant diffuse mesothelioma of the pleura: report of a case. J Oral Maxillofac Surg 1999;57:861–863.
American Joint Committee on Cancer (AJCC). AJCC cancer staging handbook, 6th ed.: TNM classification of malignant tumors. New York: Springer, 2002.
Roberts GH. Distal visceral metastases in pleural mesothelioma. Br J Dis Chest 1976;70:246–250.
Huncharek M, Muscat J. Metastases in diffuse pleural mesothelioma: influence of histological type. Thorax 1987;42:897–898.
Hulks G, Thomas JSJ, Waclawski E. Malignant pleural mesothelioma in western Glasgow 1980–6. Thorax 1989;44:496–500.
King JA, Tucker JA, Wong SW. Mesothelioma: a study of 22 gases. South Med J 1997;90:199–205.
Elmes PC, Simpson MJC. The clinical aspects of mesothelioma. Q J Med 1976;45:427–429.
Doward AJ, Stack BHR. Diffuse malignant pleural mesothelioma in Glasgow. Br J Dis Chest 1981;75:397–402.
Chahinian AP, Pajak TF, Holand JF, et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982;96:746–755.
Solomons K. Malignant mesothelioma—clinical and epidemiological features: a report of 80 cases. S Afr Med J 1984;66:407–412.
Krumhaar D, Lange S, Hartman C, Anhuth D. Follow-up study of 100 malignant pleural mesotheliomas. Thorac Cardiovasc Surg 1985;33:272–275.
Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 322 patients. J Clin Oncol 1989;7:1157–1168.
Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976;31:15–24.
Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996;14:1–12.
Ohishi N, Oka T, Fukuhara T, et al. Extensive pulmonary metastases in malignant pleural mesothelioma: a rare clinical and radiographic presentation. Chest 1996;110:296–298.
Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma: a study of 167 patients. Chest 1988;93:159–162.
Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988;6:147–153.
Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van Dor Merwe CA. Malignant pleural mesotheliom: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527–535.
Harvey JC, Fleischman EH, Kagan AR, Streeter OE. Malignant pleural mesothelioma: a survival study. J Surg Oncol 1990;45:40–42.
Ribak J, Selikoff IJ. Survival of asbestos insulation workers with mesothelioma. Br J Ind Med 1992;49:732–735.
Tammilehto L. Malignant mesothelioma: Prognostic factors in a prospective study of 98 patients. Lung Cancer 1992;8:175–184.
Sridhar KS, Doria R, Raub WA Jr, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992;70:2969–2979.
Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma, the EORTC experience. J Clin Oncol 1998;16:145–152.
Grondin SC, Sugarbaker DJ. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999;116:450S–454S.
Takagi K, Tsuchy AR, Watanabi Y. Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer 2001;31:57–65.
Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated without common malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310–317.
Edwards JG, Swinson DE, Jones JL, et al. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003;124:1916–1923.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Hammar, S.P., Henderson, D.W., Klebe, S., Dodson, R.F. (2008). Neoplasms of the Pleura. In: Tomashefski, J.F., Cagle, P.T., Farver, C.F., Fraire, A.E. (eds) Dail and Hammar’s Pulmonary Pathology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-72114-9_12
Download citation
DOI: https://doi.org/10.1007/978-0-387-72114-9_12
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-72113-2
Online ISBN: 978-0-387-72114-9
eBook Packages: MedicineMedicine (R0)